var title_f10_29_10704="Erythema migrans PI";
var content_f10_29_10704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bull's eye rash caused by tick bite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tick bites can cause a distinctive circular rash with a darkened center.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dori F Zaleznik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10704=[""].join("\n");
var outline_f10_29_10704=null;
var title_f10_29_10705="Echocardiogram apical 4-chamber Ebsteins anomaly";
var content_f10_29_10705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Echocardiogram apical 4-chamber with and without saline contrast showing Ebstein's anomaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view in Ebstein's anomaly shows an apically displaced tricuspid valve (TV) which results in an atrialized right ventricle (RV) and a small functioning right ventricle (panels A and B, left and center respectively). In panel C (right), agitated saline&nbsp;contrast has been administered for opacification of the right chambers; a small amount of contrast can be seen in the left ventricle (LV), indicating the presence of a right-to-left shunt, which almost certainly is at the atrial level.",
"    <div class=\"footnotes\">",
"     RA: right atrium; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10705=[""].join("\n");
var outline_f10_29_10705=null;
var title_f10_29_10706="Thin intertwin membrane";
var content_f10_29_10706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monochorionic diamniotic pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrow points to a thin intertwin membrane characteristic of monochorionic diamniotic twin pregnancy dividing sac A and sac B.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10706=[""].join("\n");
var outline_f10_29_10706=null;
var title_f10_29_10707="Common bile duct stone on cholangiography";
var content_f10_29_10707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common bile duct stone on cholangiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 573px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Common bile duct stone (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg, RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10707=[""].join("\n");
var outline_f10_29_10707=null;
var title_f10_29_10708="Pericardial effusion parasternal long axis echocardiogram";
var content_f10_29_10708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/76287/palaxpef_conv.mp4?title=Pericardial+effusion+parasternal+long+axis+echocardiogram\" style=\"width:324px;height:236px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal long axis view from a 2-D echocardiogram shows a moderate sized anterior and posterior pericardial effusion which also extends behind the left atrium. There is no evidence for tamponade. The interventricular septum and posterior left ventricular (LV) wall are hypertrophied.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10708=[""].join("\n");
var outline_f10_29_10708=null;
var title_f10_29_10709="Color Doppler image of velamentous umbilical cord";
var content_f10_29_10709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Color Doppler image of velamentous umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color Doppler shows flow in the umbilical vessels separate from the cord and extending to the placenta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10709=[""].join("\n");
var outline_f10_29_10709=null;
var title_f10_29_10710="Cabozantinib: Patient drug information";
var content_f10_29_10710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cabozantinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     see \"Cabozantinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16047819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cometriq&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15865079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3651282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may only get this drug from certain pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Holes in the GI (gastrointestinal) tract, wounds not fully healed, fistulas, and very bad bleeding have been reported. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15865081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat thyroid cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15865080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4085864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cabozantinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15865085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had any recent surgery or dental care, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4085882",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 4 months after your last dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15865086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count or low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in taste.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3001761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Redness or irritation of the palms of hands or soles of feet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15865087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in skin on hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15865083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15865084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is less than 12 hours until the next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4089602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is more than 12 hours until your next dose, take the missed dose as right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15865088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15865089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87616 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10710=[""].join("\n");
var outline_f10_29_10710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16047819\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865079\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865081\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865080\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865085\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865086\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865087\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865083\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865084\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865088\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15865089\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=related_link\">",
"      Cabozantinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_29_10711="Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma";
var content_f10_29_10711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10711/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10711/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10711/contributors\">",
"     Richard T Hoppe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10711/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10711/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10711/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10711/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/29/10711/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of Hodgkin lymphoma (formerly called Hodgkin's disease) has been established, subsequent therapy and prognosis are based upon the stage of the disease. Among patients with stage I-II disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definitions of favorable and unfavorable prognosis stage I-II Hodgkin lymphoma will be reviewed here. The treatment of these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link\">",
"     \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304989434\">",
"    <span class=\"h1\">",
"     OVERVIEW OF STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ann Arbor staging system with Cotswolds modifications is the current staging system used for patients with Hodgkin lymphoma. Patients are either staged clinically or, much less often, pathologically. They are placed into one of four stages, based upon the sites of involvement, and are assigned numbers and letters that designate the number of lymph node regions involved and the presence or absence of systemic symptoms or of bulky or extended disease (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (Ie).",
"     </li>",
"     <li>",
"      Stage II &mdash; Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIe). The number of anatomic regions should be indicated by a subscript (eg, II-3).",
"     </li>",
"     <li>",
"      Stage III &mdash; Involvement of lymph node regions or lymphoid structures on both sides of the diaphragm (III) which may include the spleen (IIIs) or limited, a contiguous extralymphatic organ or site (IIIe) or both (IIIes). This may be subdivided into stage III-1 or III-2: stage III-1 is used for patients with involvement of the spleen or splenic hilar, celiac or portal nodes; and stage III-2 is used for patients with involvement of the paraaortic, iliac, inguinal, or mesenteric nodes.",
"     </li>",
"     <li>",
"      Stage IV &mdash; Diffuse or disseminated foci of involvement of one or more extralymphatic organs or tissues, with or without associated lymphatic involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All cases are subclassified to indicate the absence (A) or presence (B) of one or more of the following three systemic symptoms: significant unexplained fever, night sweats, or unexplained weight loss exceeding 10 percent of body weight during the six months prior to diagnosis.",
"   </p>",
"   <p>",
"    The subscript \"X\" is used if bulky disease is present. No subscripts are used in the absence of bulk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H14#H14\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Criteria for bulky disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subscript \"E\" is used if limited extranodal extension is documented. More extensive extranodal disease is designated stage IV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H15#H15\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Criteria for extranodal spread'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient&rsquo;s stage is currently determined based upon information gathered from a history, physical examination, chest radiograph, and integrated positron emission",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography",
"    <span class=\"nowrap\">",
"     (PET/CT)",
"    </span>",
"    scan of the chest, abdomen, and pelvis. A unilateral bone marrow aspirate and biopsy is performed for patients with stage III or IV disease and those with systemic B symptoms. CT and PET scanning should be performed as part of the staging for all patients. The use of both studies aids in staging accuracy in part because the substantial rate of false-positive results with each study tends to overstage some patients. For determination of disease below the diaphragm, the involved sites should be positive in both studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H4#H4\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Staging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with stage I or stage II disease are then further stratified for treatment purposes into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Favorable versus unfavorable disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of staging laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose staging includes, in addition to lymph node biopsy, a laparotomy with splenectomy and liver biopsy and bone marrow biopsy, are designated PS (pathologic staging); clinical stage (CS) refers to clinical and radiographic staging without laparotomy. Although staging laparotomy remains the most precise method to ascertain the presence and extent of abdominal involvement and may permit a reduction in the extent of radiation therapy or obviate the need for chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/1\">",
"     1",
"    </a>",
"    ], it is now almost never performed in routine clinical practice. This is because of the associated morbidity and the lack of survival advantage in patients with favorable prognosis disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. With the use of effective and less toxic chemotherapy, most patients with CS I-II Hodgkin lymphoma now receive chemotherapy combined with radiation therapy, thus reducing the need to identify occult abdominal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FAVORABLE VERSUS UNFAVORABLE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of prognostic factors has led to the stratification of patients with early (stage I-II) HL into favorable and unfavorable prognostic groups for different clinical trials. This stratification has led to the reduction of chemotherapy (eg, number of cycles and intensity) and radiation therapy (eg, dose and field size), especially in patients with favorable prognosis stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    disease. The definitions of favorable and unfavorable have varied by study group.",
"   </p>",
"   <p>",
"    Although many prognostic factors that have been identified have lost significance as more intensive combined radiation therapy and chemotherapy regimens have been used, some remain important in the design of clinical trials aimed at reducing the intensity of radiation therapy and chemotherapy for early stage HL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/5\">",
"     5",
"    </a>",
"    ]. Some factors are predictive of a higher risk of relapse, a lower rate of survival, or recurrence after treatment with radiation therapy alone; fewer are predictive of relapse after chemotherapy and radiation therapy, except when there is a significant reduction in the extent and intensity of both modalities. Only older age at diagnosis has been consistently found to be a significant adverse factor for survival, both after radiation therapy and after combined radiation therapy and chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H9398216#H9398216\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=see_link&amp;anchor=H17219017#H17219017\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'International Prognostic Index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1309934138\">",
"    <span class=\"h2\">",
"     Defining favorable and unfavorable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stratification of patients with early stage disease into favorable and unfavorable subsets varies by region. In the United States, most centers define early stage favorable HL as non-bulky (&lt;10 cm) stage IA-IIA disease. In contrast, European research organizations incorporate other variables, such as patient age and the erythrocyte sedimentation rate (ESR).",
"   </p>",
"   <p>",
"    The European Organization for the Research and Treatment of Cancer (EORTC) clinical trials and trials from the Princess Margaret Hospital and the German Hodgkin's Study Group (GHSG) have contributed greatly to our understanding of prognostic factors in patients with clinically staged disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. These studies evaluated patients treated with either radiation therapy or combined radiation therapy and chemotherapy. These individual risk factors are discussed in more detail in the sections that follow.",
"   </p>",
"   <p>",
"    Further understanding of these risk factors has lead to the development of several definitions of favorable versus unfavorable stage I-II HL (",
"    <a class=\"graphic graphic_table graphicRef55327 \" href=\"UTD.htm?28/63/29692\">",
"     table 2",
"    </a>",
"    ). The most popular of these systems are those of EORTC, and the GHSG.",
"   </p>",
"   <p>",
"    In the current EORTC trials, patients with any one of the following adverse factors have unfavorable prognosis CS I-II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large mediastinal adenopathy",
"     </li>",
"     <li>",
"      Involvement of four or more lymph node regions",
"     </li>",
"     <li>",
"      Age over 50 at diagnosis",
"     </li>",
"     <li>",
"      A defined combination of B symptoms and elevated ESR: B symptoms and an ESR over 30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      or an ESR over 50",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      without B symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the GHSG trials, the criteria for unfavorable prognosis are similar, however age is not an adverse factor and involvement of three or more lymphoid regions is an adverse factor (",
"    <a class=\"graphic graphic_table graphicRef55327 \" href=\"UTD.htm?28/63/29692\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At present, initial therapy of stage I-II HL is determined in part by whether they have favorable or unfavorable disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with favorable prognostic factors are candidates for involved field radiation therapy plus modified chemotherapy or, in some cases, chemotherapy alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"       \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with unfavorable prognostic factors should receive standard chemotherapy and involved field radiation therapy as initial treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link\">",
"       \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adverse prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with pathologically staged (PS) (by laparotomy) or clinical staged (CS) I-II disease, retrospective studies using multivariate analysis have identified a number of adverse prognostic criteria, including large mediastinal adenopathy, older age, and B symptoms, particularly fever and weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Large mediastinal adenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large mediastinal adenopathy (LMA; defined as more than one-third of the greatest intrathoracic diameter of the chest wall in the Ann Arbor system or as a mediastinal mass with a maximum width that is equal to or greater than one-third of the internal transverse diameter of the thorax at the level of",
"    <span class=\"nowrap\">",
"     T5/6",
"    </span>",
"    interspace in the Cotswolds system) or large tumor burden has been the major factor predicting an increased risk of relapse; the data are conflicting on whether these findings do [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/12\">",
"     12",
"    </a>",
"    ] or do not predict [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/13,14\">",
"     13,14",
"    </a>",
"    ] a lower rate of survival.",
"   </p>",
"   <p>",
"    One retrospective series of 230 patients treated with radiation therapy alone revealed a 10-year recurrence rate of 55 percent in patients with LMA compared with 17 percent for patients without LMA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of recurrences in patients with extensive thoracic Hodgkin lymphoma occur in lymph nodes or extranodal sites above the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]; most develop within the first three years after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/18\">",
"     18",
"    </a>",
"    ]. Subdiaphragmatic recurrence is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/16,18\">",
"     16,18",
"    </a>",
"    ], occurring in only 4 percent in one series of patients treated with combined chemotherapy and radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that a preferred approach is treatment with combination chemotherapy followed by involved field irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/15,16,18,19\">",
"     15,16,18,19",
"    </a>",
"    ]. In one series of 172 patients with LMA, for example, the 10-year actuarial freedom from relapse was 88 percent with combined therapy compared with 54 percent with radiation therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are only limited data with respect to the impact on outcome of bulk disease outside the mediastinum, usually because of difficulty in assessing the data from medical records. There are conflicting data as to whether the relapse rate is higher with peripheral nodes that are larger than 6 to 7 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. At present, measurement of peripheral bulk is only occasionally included as a prognostic factor to define patients as unfavorable for the purpose of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Age over 40 to 50",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients 40 years of age or older appear to have a lower survival rate (but not a higher recurrence rate) than younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/11,12,14\">",
"     11,12,14",
"    </a>",
"    ]. Two factors appear to contribute: less successful treatment at relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/22-24\">",
"     22-24",
"    </a>",
"    ], and a greater mortality risk from causes other than Hodgkin lymphoma, such as second tumors and cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Age &ge;50 years has now replaced age 40 or older as an adverse prognostic factor in EORTC trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     B symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific B symptoms in patients with Hodgkin lymphoma are defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained weight loss of more than 10 percent of body weight during the six months before initial staging investigation",
"     </li>",
"     <li>",
"      Unexplained persistent or recurrent fever with temperatures above 38&ordm;C during the previous month",
"     </li>",
"     <li>",
"      Recurrent drenching night sweats during the previous month.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although other symptoms may be associated with Hodgkin lymphoma, such as pruritus, they are not classified as B symptoms.",
"   </p>",
"   <p>",
"    Patients with stage I-II Hodgkin lymphoma who have fever and weight loss have reductions in survival (57 percent at seven years in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/27\">",
"     27",
"    </a>",
"    ]) and freedom from relapse, whether treated by radiation therapy alone or combined modality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/11,27-29\">",
"     11,27-29",
"    </a>",
"    ]. In comparison, patients with night sweats alone who are treated with radiation therapy appear to have a prognosis similar to that of patients with PS IA-IIA disease without night sweats. In a multivariate analysis of patients with single B symptoms, the relative relapse risk was 4.3 for fevers, 2.4 for weight loss, and 0.8 for night sweats [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other adverse risk factors in patients with stage I-II disease, which have been derived from radiographic staging or pathologic staging following laparotomy, include an elevated erythrocyte sedimentation rate and a high number of sites involved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10711/abstract/7,8,11,30\">",
"     7,8,11,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304989440\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of Hodgkin lymphoma (HL) has been established, subsequent therapy and prognosis are based upon the stage of the disease. Patients with HL are staged according to the Ann Arbor staging system with Cotswolds modifications most frequently based upon information gathered from a history, physical examination, chest radiograph, and integrated positron emission",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography",
"    <span class=\"nowrap\">",
"     (PET/CT)",
"    </span>",
"    scan of the chest, abdomen, and pelvis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H4#H4\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Staging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using this system, patients are placed into one of four stages, based upon the sites of involvement, and are assigned numbers and letters that designate the number of nodes involved and the presence or absence of systemic symptoms or of bulky or extended disease (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among patients with stage I or II disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features. The definitions of favorable and unfavorable have varied by study group. The two most popular systems are those of the European Organization for the Research and Treatment of Cancer (EORTC) and the German Hodgkin's Study Group (GHSG). (See",
"    <a class=\"local\" href=\"#H1309934138\">",
"     'Defining favorable and unfavorable disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the current EORTC trials, patients with clinical stage I or II disease plus any one of the following adverse factors are classified as early stage unfavorable disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large mediastinal adenopathy",
"     </li>",
"     <li>",
"      Involvement of four or more lymph node regions",
"     </li>",
"     <li>",
"      Age over 50 at diagnosis",
"     </li>",
"     <li>",
"      A defined combination of B symptoms and elevated erythrocyte sedimentation rate (ESR): B symptoms and an ESR over 30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      or an ESR over 50",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      without B symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the GHSG trials, the criteria for unfavorable prognosis are similar, however age is not an adverse factor and involvement of three or more lymphoid regions is an adverse factor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A favorable prognostic group was defined in the H7 and H8 EORTC trials as age 50 or under; without large mediastinal adenopathy; an ESR of less than",
"      <span class=\"nowrap\">",
"       50/h",
"      </span>",
"      and no B symptoms or an ESR of less than 30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      with B symptoms; and disease limited to one to three regions of involvement.",
"     </li>",
"     <li>",
"      An unfavorable prognostic group was defined in the H7 and H8 EORTC trials as those having any one of the following features: large mediastinal adenopathy; four or more sites of involvement; B symptoms and an ESR over 30",
"      <span class=\"nowrap\">",
"       mm/hour;",
"      </span>",
"      an ESR over 50",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      without B symptoms; or age over 50.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, initial therapy of stage I-II HL is determined in part by whether they have favorable or unfavorable disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with favorable prognostic factors are candidates for involved field radiation therapy plus modified chemotherapy or, in some cases, chemotherapy alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"       \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with unfavorable prognostic factors should receive standard chemotherapy and involved field radiation therapy as initial treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link\">",
"       \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/1\">",
"      Mauch P, Larson D, Osteen R, et al. Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 1990; 8:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/2\">",
"      Ng AK, Weeks JC, Mauch PM, Kuntz KM. Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. J Clin Oncol 1999; 17:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/3\">",
"      Advani RH, Horning SJ. Treatment of early-stage Hodgkin's disease. Semin Hematol 1999; 36:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/4\">",
"      Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999; 93:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/5\">",
"      Advani RH, Hoppe RT, Maeda LS, et al. Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys 2011; 81:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/6\">",
"      Mauch PM. Controversies in the management of early stage Hodgkin's disease. Blood 1994; 83:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/7\">",
"      Gospodarowicz MK, Sutcliffe SB, Clark RM, et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Oncol Biol Phys 1992; 22:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/8\">",
"      Henry-Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991; 114:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/9\">",
"      Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989; 73:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/10\">",
"      D&uuml;hmke E, Diehl V, Loeffler M, et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 1996; 36:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/11\">",
"      Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 1992; 28A:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/12\">",
"      Specht L, Nordentoft AM, Cold S, et al. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 1988; 61:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/13\">",
"      Hoppe RT, Coleman CN, Cox RS, et al. The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982; 59:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/14\">",
"      Mauch P, Tarbell N, Weinstein H, et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/15\">",
"      Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 1978; 42:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/16\">",
"      Leopold KA, Canellos GP, Rosenthal D, et al. Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol 1989; 7:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/17\">",
"      Schomberg PJ, Evans RG, O'Connell MJ, et al. Prognostic significance of mediastinal mass in adult Hodgkin's disease. Cancer 1984; 53:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/18\">",
"      Hughes-Davies L, Tarbell NJ, Coleman CN, et al. Stage IA-IIB Hodgkin's disease: management and outcome of extensive thoracic involvement. Int J Radiat Oncol Biol Phys 1997; 39:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/19\">",
"      Mauch P, Gorshein D, Cunningham J, Hellman S. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat Rep 1982; 66:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/20\">",
"      Mendenhall NP, Cantor AB, Barr&eacute; DM, et al. The role of prognostic factors in treatment selection for early-stage Hodgkin's disease. Am J Clin Oncol 1994; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/21\">",
"      Bonadonna G, Valagussa P, Santoro A. Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv 1985; 4:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/22\">",
"      Roach M 3rd, Brophy N, Cox R, et al. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/23\">",
"      Healey EA, Tarbell NJ, Kalish LA, et al. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer 1993; 71:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/24\">",
"      Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/25\">",
"      Henry-Amar M. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease. J Natl Cancer Inst 1983; 71:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/26\">",
"      Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 1982; 307:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/27\">",
"      Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM. Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 1987; 5:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/28\">",
"      Anderson H, Deakin DP, Wagstaff J, et al. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group. Br J Cancer 1984; 49:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/29\">",
"      Tubiana M, Henry-Amar M, Hayat M, et al. The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy. Int J Radiat Oncol Biol Phys 1984; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10711/abstract/30\">",
"      Liao Z, Ha CS, Vlachaki MT, et al. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2001; 50:971.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4685 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-08F48505D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10711=[""].join("\n");
var outline_f10_29_10711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1304989440\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304989434\">",
"      OVERVIEW OF STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of staging laparotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FAVORABLE VERSUS UNFAVORABLE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1309934138\">",
"      Defining favorable and unfavorable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adverse prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Large mediastinal adenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Age over 40 to 50",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - B symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304989440\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4685\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4685|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/23/19836\" title=\"table 1\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/63/29692\" title=\"table 2\">",
"      Unfavorable prognostic factors early HL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=related_link\">",
"      Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_29_10712="Clinical manifestations and diagnosis of Fusarium infection";
var content_f10_29_10712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Fusarium infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10712/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10712/contributors\">",
"     Elias Anaissie, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10712/contributors\">",
"     Marcio Nucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10712/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10712/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10712/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/29/10712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H773301914\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species cause a broad spectrum of infections in humans, including superficial infections such as keratitis and onychomycosis, as well as locally invasive and disseminated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/1\">",
"     1",
"    </a>",
"    ]. Invasive and disseminated infections occur almost exclusively in severely immunocompromised patients, particularly among those with prolonged and profound neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe T cell immunodeficiency. Among patients with hematologic malignancy, the infection predominates during periods of neutropenia, typically among patients with leukemia receiving induction chemotherapy.",
"   </p>",
"   <p>",
"    Fusarium species may also cause allergic diseases such as sinusitis in immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/2\">",
"     2",
"    </a>",
"    ], and mycotoxicosis following ingestion of food contaminated by toxin-producing Fusarium species [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/3\">",
"     3",
"    </a>",
"    ]. Fusarium species are also important plant pathogens that cause various diseases of cereal grains [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/3\">",
"     3",
"    </a>",
"    ], and occasionally cause infection in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of fusariosis will be reviewed here. The mycology, pathogenesis, epidemiology, treatment, and prevention of fusariosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link\">",
"     \"Treatment and prevention of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773300992\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301000\">",
"    <span class=\"h2\">",
"     Immunocompetent patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratitis and onychomycosis are the most common manifestations of fusariosis among immunocompetent hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301007\">",
"    <span class=\"h3\">",
"     Keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratitis is inflammation of the cornea, and can be caused by a variety of infectious and non-infectious causes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1044205999\">",
"     'Keratitis'",
"    </a>",
"    below.) Fusarium spp are a common cause of fungal keratitis, and were responsible for an outbreak among contact lens users between 2004 and 2006, which was linked to a specific brand of contact lens solution, ReNu with MoistureLoc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link&amp;anchor=H420413563#H420413563\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of fusarial keratitis are similar to keratitis caused by other agents and include eye pain, light sensitivity, conjunctival injection, and tearing; discharge is usually absent (",
"    <a class=\"graphic graphic_picture graphicRef80460 \" href=\"UTD.htm?8/4/8256\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/5\">",
"     5",
"    </a>",
"    ]. Compared with bacterial keratitis, patients with fungal keratitis typically have fewer inflammatory signs and symptoms and can have a more indolent presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/5\">",
"     5",
"    </a>",
"    ]. In later stages, suppuration and a hypopyon may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/5\">",
"     5",
"    </a>",
"    ]. Keratitis may result in corneal perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301014\">",
"    <span class=\"h3\">",
"     Onychomycosis and superficial skin infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of fusarial onychomycosis are similar to those seen with other fungi. The infection begins as whitish, yellowish, or brownish discoloration of one part of the nail, and gradually extends to cover it completely. Some features suggest a fusarial etiology for the onychomycosis, including a predilection for the toenails rather than the fingernails, involvement of the proximal subungual areas, and coexisting subacute or acute paronychia (",
"    <a class=\"graphic graphic_picture graphicRef78755 \" href=\"UTD.htm?15/3/15422\">",
"     picture 2",
"    </a>",
"    )",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/6\">",
"     6",
"    </a>",
"    ]. Preexisting damage to the nail",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection by dermatophytes may predispose patients to fusarial onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fusarium species may also cause superficial infections typical of dermatophytes, such as intertrigo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/7\">",
"     7",
"    </a>",
"    ], tinea pedis, and hyperkeratotic plantar lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/8\">",
"     8",
"    </a>",
"    ]. The contribution of Fusarium species to non-dermatophyte skin infections appears to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301021\">",
"    <span class=\"h3\">",
"     Deep cutaneous infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to superficial infections, Fusarium species may infect deeper layers of the skin in immunocompetent hosts. Lesions are usually localized and occur after skin breakdown, such as at sites of trauma, burns, or preexisting onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/10\">",
"     10",
"    </a>",
"    ]. Cellulitis, ulcers (",
"    <a class=\"graphic graphic_picture graphicRef61489 \" href=\"UTD.htm?16/12/16577\">",
"     picture 3",
"    </a>",
"    ), abscesses, and lesions resembling chromoblastomycosis and mycetoma have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301028\">",
"    <span class=\"h3\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species may occasionally cause other infections in immunocompetent hosts, including chronic sinusitis, pneumonia, endophthalmitis, osteomyelitis, septic arthritis, brain abscess, cystitis, and peritonitis (",
"    <a class=\"graphic graphic_table graphicRef64555 \" href=\"UTD.htm?8/5/8285\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/10-22\">",
"     10-22",
"    </a>",
"    ]. The clinical manifestations of these infections are similar to those caused by other fungal pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301035\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentation of fusarial infection in immunosuppressed patients is persistent fever refractory to antibacterial and antifungal therapy in the setting of profound and prolonged neutropenia. Other findings at presentation may include sinusitis, pneumonia, cellulitis at the site of preexisting skin breakdown, and metastatic skin lesion. Endophthalmitis, rhinocerebral infection, myositis, and infections of the central nervous system have also been reported (",
"    <a class=\"graphic graphic_table graphicRef64555 \" href=\"UTD.htm?8/5/8285\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/1,23-25\">",
"     1,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of fusariosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link&amp;anchor=H4#H4\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301042\">",
"    <span class=\"h3\">",
"     Sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinusitis caused by Fusarium species may develop either as a single organ infection or coexist with fusarial pneumonia. When immunosuppression is severe, sinusitis may result in disseminated fusariosis. The clinical manifestations of fusarial sinusitis are indistinguishable from those caused by Aspergillus species, including nasal discharge and obstruction, with a propensity for periorbital and paranasal cellulitis (",
"    <a class=\"graphic graphic_picture graphicRef62828 \" href=\"UTD.htm?5/47/5873\">",
"     picture 4",
"    </a>",
"    )",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/23\">",
"     23",
"    </a>",
"    ]. Necrosis of the mucosa is a hallmark, and is a consequence of the angioinvasive nature of these mycoses (",
"    <a class=\"graphic graphic_picture graphicRef75603 \" href=\"UTD.htm?34/41/35487\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301049\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung involvement is common in invasive fusariosis in immunocompromised hosts. In patients with disseminated infection, pneumonia may be the primary site of the infection or may be secondary to hematogenous dissemination. The clinical presentation is usually non-specific, with some patients presenting with a clinical picture similar to that seen in invasive aspergillosis, including dry cough, pleuritic chest pain, and shortness of breath.",
"   </p>",
"   <p>",
"    Radiographic findings include alveolar infiltrates (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50014 \" href=\"UTD.htm?33/5/33872\">",
"     image 1",
"    </a>",
"    ), nodules with or without the halo sign (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51721 \" href=\"UTD.htm?17/5/17489\">",
"     image 2",
"    </a>",
"    ), and cavitary lesions, particularly when fusarial pneumonia is the only site of infection",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301056\">",
"    <span class=\"h3\">",
"     Cutaneous lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarial skin lesions in immunocompromised patients may be either localized or disseminated. Localized lesions usually present as cellulitis at sites of skin breakdown caused by trauma or onychomycosis (",
"    <a class=\"graphic graphic_picture graphicRef50045 \" href=\"UTD.htm?0/31/511\">",
"     picture 6",
"    </a>",
"    ). Lymphangitic spread may be seen and the infection may progress to cause disseminated fusariosis. Patients with disseminated disease may develop multiple erythematous papular or nodular and painful lesions, frequently with central necrosis giving the lesions an ecthyma gangrenosum-like appearance (",
"    <a class=\"graphic graphic_picture graphicRef54774 \" href=\"UTD.htm?41/3/42046\">",
"     picture 7",
"    </a>",
"    ). Target lesions, which have a thin rim of erythema of 1 to 3 cm in diameter surrounding papular or nodular lesions, are present in &lt;10 percent of patients (",
"    <a class=\"graphic graphic_picture graphicRef64575 \" href=\"UTD.htm?5/43/5809\">",
"     picture 8",
"    </a>",
"    ), and bullae are very rare (",
"    <a class=\"graphic graphic_picture graphicRef77327 \" href=\"UTD.htm?2/7/2162\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fusarial metastatic skin lesions may involve any site, with predominance for the extremities, and evolve rapidly, usually over a few days (",
"    <a class=\"graphic graphic_picture graphicRef74279 \" href=\"UTD.htm?12/6/12386\">",
"     picture 10",
"    </a>",
"    ). Approximately one third of the patients with disseminated fusariosis and skin lesions present with lesions at different stages of evolution (papules, nodules, and necrotic lesions) (",
"    <a class=\"graphic graphic_picture graphicRef55873 \" href=\"UTD.htm?35/32/36352\">",
"     picture 11",
"    </a>",
"    ); concomitant myalgias (suggesting muscle involvement) occurred in 15 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301063\">",
"    <span class=\"h3\">",
"     Fungemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to aspergillosis and most other invasive mold infections, a striking characteristic of fusarial infections in immunocompromised hosts is the high frequency of positive blood cultures. This is probably because Fusarium species sporulate in vivo, facilitating hematogenous dissemination and hence a high rate of positive blood cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H773301077\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among 294 cases of invasive fusariosis in immunocompromised hosts, blood cultures were positive in 199 patients (41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/1\">",
"     1",
"    </a>",
"    ]. Although fungemia typically occurs in the context of disseminated disease, occasional cases of fungemia without organ involvement have been reported, some of which were related to central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/27-33\">",
"     27-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301070\">",
"    <span class=\"h3\">",
"     Disseminated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated disease is the most frequent clinical form of fusariosis in immunocompromised patients, occurring in approximately 70 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/1\">",
"     1",
"    </a>",
"    ]. It may present as antibiotic-refractory fever in patients with prolonged (&gt;10 days) and profound (&lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3)",
"    </span>",
"    neutropenia with subsequent development of widespread cutaneous lesions and positive blood cultures (",
"    <a class=\"graphic graphic_picture graphicRef64575 \" href=\"UTD.htm?5/43/5809\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74279 \" href=\"UTD.htm?12/6/12386\">",
"     picture 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55873 \" href=\"UTD.htm?35/32/36352\">",
"     picture 11",
"    </a>",
"    ). Involvement of other sites (either as primary or secondary infections) may be seen, particularly pneumonia, sinusitis and extremity cellulitis. A clue to the diagnosis of disseminated fusariosis is the presence of refractory fever in a profoundly neutropenic patient with multiple skin lesions and a blood culture growing a mold.",
"   </p>",
"   <p>",
"    Disseminated Fusarium infections are associated with poor outcomes, with mortality rates of 60 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/1,34-37\">",
"     1,34-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link&amp;anchor=H5519506#H5519506\">",
"     \"Treatment and prevention of Fusarium infection\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871851998\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of fusariosis depends upon the host&rsquo;s immune status and the site(s) of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1044205999\">",
"    <span class=\"h2\">",
"     Keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of microbes can cause keratitis, including bacteria (eg, staphylococci, streptococci, gram-negative bacilli, Nocardia spp, mycobacteria), viruses (eg, herpes simplex virus, varicella-zoster virus, adenovirus), fungi, and parasites including the free-living protozoan, Acanthamoeba [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/5\">",
"     5",
"    </a>",
"    ]. Fusarium is a common cause of fungal keratitis, but other possible causes include Candida spp, Aspergillus spp, and others. Both Fusarium spp and Acanthamoeba have been associated with outbreaks among contact lens users [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Culturing corneal scrapings is essential for establishing the diagnosis of keratitis when an infectious cause of keratitis is suspected because the microbial etiology cannot be determined based upon the clinical presentation. (See",
"    <a class=\"local\" href=\"#H773301077\">",
"     'Diagnosis'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Non-infectious causes of keratitis include trauma, hypersensitivity reactions, and immune-mediated conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H957967710\">",
"    <span class=\"h2\">",
"     Onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of onychomycosis includes dermatophytes (eg, Trichophyton rubrum), which are by far the most common cause, and, less commonly, molds, such as Scopulariopsis brevicaulis and Aspergillus spp. Candida spp can also cause onychomycosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=see_link&amp;anchor=H2#H2\">",
"     \"Onychomycosis\", section on 'Epidemiology and microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1044205898\">",
"    <span class=\"h2\">",
"     Invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with invasive disease, including sinusitis, pneumonia, and disseminated disease, fusariosis is most often confused with aspergillosis since both Fusarium and Aspergillus spp cause similar clinical manifestations and appear similar on histopathology, with branching septate hyphae. Infection with Fusarium spp is much more likely to cause positive blood cultures than Aspergillus spp and other molds, and is more commonly associated with onychomycosis as the source of systemic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H773301077\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the diagnosis of fusariosis depends upon the clinical form of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817799183\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the diagnosis is confirmed by the isolation of Fusarium species in cultures of involved biologic materials, such as nail scrapings (onychomycosis), corneal scrapings (keratitis), skin biopsy (metastatic skin lesions), sinus aspirates (sinusitis), respiratory secretions (pneumonia),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood cultures (fungemia, disseminated disease). Tissue biopsy with culture and histopathology provides definitive evidence of invasive disease. The following discussion focuses on invasive Fusarium infections in immunocompromised hosts.",
"   </p>",
"   <p>",
"    In severely immunocompromised patients, two characteristics suggest the diagnosis of disseminated fusariosis: the presence of skin lesions (either cellulitis at sites of skin breakdown caused by trauma or onychomycosis, or metastatic lesions) and mold growing from blood cultures (",
"    <a class=\"graphic graphic_figure graphicRef80289 \" href=\"UTD.htm?9/19/9528\">",
"     figure 1",
"    </a>",
"    ). Skin biopsies should be performed in all immunocompromised patients with suspicious skin lesions, and should be sent for both histopathology and microbiology studies. Blood cultures should also be obtained. In individuals with lung involvement, a sputum sample should be sent for fungal stain and culture as well as other microbiologic studies when feasible. (See",
"    <a class=\"local\" href=\"#H1044205955\">",
"     'Histopathology'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1044205941\">",
"     'Blood cultures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the diagnosis has not been established by skin biopsy, blood culture, or sputum fungal stain and culture, then an attempt should be made to obtain a biopsy of involved tissues (eg, lungs, sinuses). (See",
"    <a class=\"local\" href=\"#H1044205955\">",
"     'Histopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of immunocompromised patients with fusariosis should be accompanied by a clinical and radiologic assessment of disease extent, including computed tomography (CT) of the paranasal sinuses and chest.",
"   </p>",
"   <p>",
"    Patients with radiographic findings that are suggestive of an invasive fungal infection of the lungs, in whom previously obtained specimens (eg, sputum fungal stain and culture, blood cultures, skin biopsy) have not yielded a diagnosis, should ideally undergo bronchoscopy with bronchoalveolar lavage. Lung biopsy should be performed if feasible. The diagnostic approach for such patients is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486494#H1064486494\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Approach to diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1044205941\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike patients with aspergillosis, blood cultures are frequently positive in fusariosis, possibly due to the fact that Fusarium spp sporulate in vivo, facilitating dissemination and growth in the bloodstream [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/26\">",
"     26",
"    </a>",
"    ]. Blood cultures are positive in approximately 40 percent of patients with invasive fusariosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1044205948\">",
"    <span class=\"h2\">",
"     Growth of cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species grow rapidly on many media that do not contain cycloheximide, which inhibits its growth. On potato dextrose agar, Fusarium species produce white, lavender, pink, salmon, or gray-colored colonies with velvety or cottony surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interpretation of fusarial growth from different specimen types depends upon several variables, with the patient&rsquo;s immune status representing the single most important factor. For example, culture of Fusarium spp from sinus aspirates or respiratory secretions in severely immunocompromised hosts should always be considered diagnostic of fusarial infection, whereas the growth of Fusarium spp from skin scrapings in an immunocompetent host may represent colonization or contamination of laboratory specimens. Pseudo-outbreaks of fusariosis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cultures, the production of both fusoid macroconidia (hyaline, multicellular, banana-like clusters with foot cells at the base) (",
"    <a class=\"graphic graphic_picture graphicRef72385 \" href=\"UTD.htm?25/6/25701\">",
"     picture 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61073 \" href=\"UTD.htm?7/27/7602\">",
"     picture 13",
"    </a>",
"    ), and microconidia (hyaline, unicellular, ovoid to cylindrical) are characteristic of the genus Fusarium and are important in identification of different species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1044205955\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of fusariosis may require histopathologic confirmation. In tissue, the hyphae are similar to those observed in aspergillosis and scedosporiosis as narrow (3 to 8 microns wide), septated hyaline hyphae with dichotomous acute angle (45&deg;) branching (",
"    <a class=\"graphic graphic_picture graphicRef69801 \" href=\"UTD.htm?20/16/20738\">",
"     picture 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74308 \" href=\"UTD.htm?23/33/24080\">",
"     picture 15",
"    </a>",
"    ). Adventitious sporulation, which is the ability to sporulate in tissue and blood, may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/26\">",
"     26",
"    </a>",
"    ]; the identification of hyphal and yeast-like structures in the same specimen is highly suggestive of fusariosis in high-risk patients. Because of the histopathologic similarities between fusariosis and other mold infections, a definitive diagnosis requires microbial growth or species identification using in-situ hybridization in paraffin embedded tissue specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The site of biopsy depends upon the clinical manifestations in each patient, but the skin is a frequent site of infection and is the most accessible site for biopsy when multiple sites are affected. In a study of 181 patients with fusariosis (148 of whom had disseminated skin lesions), the skin was the only source of diagnostic material in 55 percent of the patients. Furthermore, skin lesions preceded fungemia in a significant proportion of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/10\">",
"     10",
"    </a>",
"    ]. Skin biopsies are safe and easy to perform, and may provide a rapid diagnosis. Tissue biopsies should always be sent for microbiologic (direct exam and culture) and histopathologic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1044205962\">",
"    <span class=\"h2\">",
"     Beta-D-glucan and galactomannan antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having an invasive fungal infection sometimes undergo 1,3-beta-D-glucan and Aspergillus galactomannan antigen testing. Although a positive 1,3-beta-D-glucan assay is suggestive of an invasive fungal infection, its lack of specificity does not help to establish Fusarium spp as the cause [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The Aspergillus galactomannan antigen assay is a fairly specific test for invasive aspergillosis, but Fusarium species have been reported to cross-react with this assay [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486430#H1064486430\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Galactomannan antigen detection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486465#H1064486465\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Beta-D-glucan assay'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817800177\">",
"    <span class=\"h2\">",
"     Other techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other techniques for the diagnosis of fusariosis include the polymerase chain reaction (PCR) and in situ hybridization. Neither technique is performed routinely. Reference laboratories use PCR-based techniques for species identification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link&amp;anchor=H516901982#H516901982\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\", section on 'Species identification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In situ hybridization can be performed on histopathology specimens showing hyphal forms when the cultures are negative in order to identify the mold [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10712/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524570574\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fusarium species cause a broad spectrum of infections in humans including superficial infections such as keratitis and onychomycosis, as well as locally invasive and disseminated infections; invasive and disseminated infections occur almost exclusively in severely immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H773301914\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presentation of fusarial infection in immunosuppressed patients is persistent fever refractory to antibacterial and antifungal therapy in the setting of profound and prolonged neutropenia. Other findings at presentation may include sinusitis, pneumonia, cellulitis at the site of preexisting skin breakdown, and metastatic skin lesions. Endophthalmitis, rhinocerebral infection, myositis, and infections of the central nervous system have also been reported (",
"      <a class=\"graphic graphic_table graphicRef64555 \" href=\"UTD.htm?8/5/8285\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H773301035\">",
"       'Immunocompromised patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to aspergillosis and most other invasive mold infections, a striking characteristic of fusarial infections in immunocompromised hosts is the high frequency of positive blood cultures and metastatic skin lesions. Disseminated disease is the most frequent clinical form of fusariosis in immunocompromised patients, occurring in approximately 70 percent of such patients. (See",
"      <a class=\"local\" href=\"#H773301063\">",
"       'Fungemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H773301070\">",
"       'Disseminated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of fusariosis is confirmed by the isolation of Fusarium species in cultures of involved biologic materials, such as nail scrapings (onychomycosis), corneal scrapings (keratitis), skin biopsy (metastatic skin lesions), sinus aspirates (sinusitis), respiratory secretions (pneumonia),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood cultures (fungemia, disseminated disease). Tissue biopsy with culture and histopathology provides definitive evidence of invasive disease. (See",
"      <a class=\"local\" href=\"#H1817799183\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In severely immunocompromised patients, two characteristics suggest the diagnosis of disseminated fusariosis: the presence of skin lesions (either cellulitis at sites of skin breakdown caused by trauma or onychomycosis, or metastatic lesions) and mold growing from blood cultures (",
"      <a class=\"graphic graphic_figure graphicRef80289 \" href=\"UTD.htm?9/19/9528\">",
"       figure 1",
"      </a>",
"      ). Skin biopsies should be performed in all immunocompromised patients with suspicious skin lesions, and should be sent for both histopathology and microbiology studies. Blood cultures should also be obtained. In individuals with lung involvement, a sputum sample should be sent for fungal stain and culture as well as other microbiologic studies when feasible. (See",
"      <a class=\"local\" href=\"#H1817799183\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In tissue, the hyphae of Fusarium spp are similar to those observed in aspergillosis and scedosporiosis as narrow (3 to 8 microns wide), septated hyaline hyphae with dichotomous acute angle (45&deg;) branching (",
"      <a class=\"graphic graphic_picture graphicRef69801 \" href=\"UTD.htm?20/16/20738\">",
"       picture 14",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef74308 \" href=\"UTD.htm?23/33/24080\">",
"       picture 15",
"      </a>",
"      ). Adventitious sporulation, which is the ability to sporulate in tissue and blood, may be present; the identification of hyphal and yeast-like structures in the same specimen is highly suggestive of fusariosis in high-risk patients. (See",
"      <a class=\"local\" href=\"#H1044205955\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation of immunocompromised patients with fusariosis should be accompanied by a clinical and radiologic assessment of disease extent, including computed tomography of the paranasal sinuses and chest. Serum galactomannan antigen testing may be positive. (See",
"      <a class=\"local\" href=\"#H1817799183\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/1\">",
"      Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/2\">",
"      Wickern GM. Fusarium allergic fungal sinusitis. J Allergy Clin Immunol 1993; 92:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/3\">",
"      Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/4\">",
"      Evans J, Levesque D, de Lahunta A, Jensen HE. Intracranial fusariosis: a novel cause of fungal meningoencephalitis in a dog. Vet Pathol 2004; 41:510.",
"     </a>",
"    </li>",
"    <li>",
"     Barnes SD, Pavan-Langston D, Azar DT. Microbial keratitis. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th edition, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. Vol 1, p.1539.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/6\">",
"      Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br J Dermatol 1997; 136:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/7\">",
"      Calado NB, Sousa F Jr, Gomes NO, et al. Fusarium nail and skin infection: a report of eight cases from Natal, Brazil. Mycopathologia 2006; 161:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/8\">",
"      Hay RJ. Fusarium infections of the skin. Curr Opin Infect Dis 2007; 20:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/9\">",
"      Guilhermetti E, Takahachi G, Shinobu CS, Svidzinski TI. Fusarium spp. as agents of onychomycosis in immunocompetent hosts. Int J Dermatol 2007; 46:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/10\">",
"      Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/11\">",
"      Rippon JW, Larson RA, Rosenthal DM, Clayman J. Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: three cases and review of the literature. Mycopathologia 1988; 101:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/12\">",
"      Kerr CM, Perfect JR, Craven PC, et al. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med 1983; 99:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/13\">",
"      Flynn JT, Meislich D, Kaiser BA, et al. Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Perit Dial Int 1996; 16:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/14\">",
"      Kurien M, Anandi V, Raman R, Brahmadathan KN. Maxillary sinus fusariosis in immunocompetent hosts. J Laryngol Otol 1992; 106:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/15\">",
"      Madhavan M, Ratnakar C, Veliath AJ, et al. Primary disseminated fusarial infection. Postgrad Med J 1992; 68:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/16\">",
"      Sander A, Beyer U, Amberg R. Systemic Fusarium oxysporum infection in an immunocompetent patient with an adult respiratory distress syndrome (ARDS) and extracorporal membrane oxygenation (ECMO). Mycoses 1998; 41:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/17\">",
"      Murray CK, Beckius ML, McAllister K. Fusarium proliferatum superficial suppurative thrombophlebitis. Mil Med 2003; 168:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/18\">",
"      Sturm AW, Grave W, Kwee WS. Disseminated Fusarium oxysporum infection in patient with heatstroke. Lancet 1989; 1:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/19\">",
"      Pflugfelder SC, Flynn HW, Jr., et al. fungal endophthalmitis. Ophthlamology 1988; 95:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/20\">",
"      Gabriele P, Hutchins RK. Fusarium endophthalmitis in an intravenous drug abuser. Am J Ophthalmol 1996; 122:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/21\">",
"      Jakle C, Leek JC, Olson DA, Robbins DL. Septic arthritis due to Fusarium solani. J Rheumatol 1983; 10:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/22\">",
"      Bourguignon RL, Walsh AF, Flynn JC, et al. Fusarium species osteomyelitis. Case report. J Bone Joint Surg Am 1976; 58:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/23\">",
"      Nucci M, Anaissie E. Emerging fungi. Infect Dis Clin North Am 2006; 20:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/24\">",
"      Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988; 67:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/25\">",
"      Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) 2011; 90:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/26\">",
"      Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 1998; 109:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/27\">",
"      Ammari LK, Puck JM, McGowan KL. Catheter-related Fusarium solani fungemia and pulmonary infection in a patient with leukemia in remission. Clin Infect Dis 1993; 16:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/28\">",
"      Castagnola E, Garaventa A, Conte M, et al. Survival after fungemia due to Fusarium moniliforme in a child with neuroblastoma. Eur J Clin Microbiol Infect Dis 1993; 12:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/29\">",
"      Eljaschewitsch J, Sandfort J, Tintelnot K, et al. Port-a-cath-related Fusarium oxysporum infection in an HIV-infected patient: treatment with liposomal amphotericin B. Mycoses 1996; 39:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/30\">",
"      Kiehn TE, Nelson PE, Bernard EM, et al. Catheter-associated fungemia caused by Fusarium chlamydosporum in a patient with lymphocytic lymphoma. J Clin Microbiol 1985; 21:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/31\">",
"      Musa MO, Al Eisa A, Halim M, et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol 2000; 108:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/32\">",
"      Raad I, Hachem R. Treatment of central venous catheter-related fungemia due to Fusarium oxysporum. Clin Infect Dis 1995; 20:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/33\">",
"      Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis 1995; 14:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/34\">",
"      Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/35\">",
"      Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994; 28 Suppl 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/36\">",
"      Gamis AS, Gudnason T, Giebink GS, Ramsay NK. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis 1991; 13:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/37\">",
"      Venditti M, Micozzi A, Gentile G, et al. Invasive Fusarium solani infections in patients with acute leukemia. Rev Infect Dis 1988; 10:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/38\">",
"      Bullock JD, Warwar RE. Contact lens solution-associated Acanthamoeba and Fusarium keratitis. Emerg Infect Dis 2010; 16:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/39\">",
"      Tu EY, Joslin CE. Recent outbreaks of atypical contact lens-related keratitis: what have we learned? Am J Ophthalmol 2010; 150:602.",
"     </a>",
"    </li>",
"    <li>",
"     Silveira FP, Queiroz-Telles F, Nucci M. Invasive mold infections. In: Diagnosis of fungal infections, Maertens JA, Marr KA (Eds), Informa Healthcare, 2007. p.171.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/41\">",
"      Grigis A, Farina C, Symoens F, et al. Nosocomial pseudo-outbreak of Fusarium verticillioides associated with sterile plastic containers. Infect Control Hosp Epidemiol 2000; 21:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/42\">",
"      Hayden RT, Isotalo PA, Parrett T, et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 2003; 12:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/43\">",
"      Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/44\">",
"      Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1--&gt;3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/45\">",
"      Aquino VR, Goldani LZ, Pasqualotto AC. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 2007; 163:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10712/abstract/46\">",
"      Tortorano AM, Esposto MC, Prigitano A, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012; 50:1051.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16218 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10712=[""].join("\n");
var outline_f10_29_10712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H524570574\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H773301914\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H773300992\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H773301000\">",
"      Immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301007\">",
"      - Keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301014\">",
"      - Onychomycosis and superficial skin infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301021\">",
"      - Deep cutaneous infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301028\">",
"      - Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H773301035\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301042\">",
"      - Sinusitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301049\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301056\">",
"      - Cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301063\">",
"      - Fungemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H773301070\">",
"      - Disseminated disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H871851998\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1044205999\">",
"      Keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H957967710\">",
"      Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1044205898\">",
"      Invasive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H773301077\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1817799183\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1044205941\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1044205948\">",
"      Growth of cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1044205955\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1044205962\">",
"      Beta-D-glucan and galactomannan antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1817800177\">",
"      Other techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H524570574\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16218|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/5/33872\" title=\"diagnostic image 1\">",
"      Fusarium pneumonia x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/5/17489\" title=\"diagnostic image 2\">",
"      Fusarium pneumonia CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16218|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/19/9528\" title=\"figure 1\">",
"      Fusarium diagnostic clues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16218|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/4/8256\" title=\"picture 1\">",
"      Contact lens-associated fungal keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/3/15422\" title=\"picture 2\">",
"      Fusarium finger cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/12/16577\" title=\"picture 3\">",
"      Skin ulcer caused by Fusarium spp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/47/5873\" title=\"picture 4\">",
"      Fusarium paranasal cellulitis and skin nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/41/35487\" title=\"picture 5\">",
"      Fusarium infection hard palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/31/511\" title=\"picture 6\">",
"      Fusarium toe cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/3/42046\" title=\"picture 7\">",
"      Fusarium cutaneous nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/43/5809\" title=\"picture 8\">",
"      Fusarium skin lesions on lower extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/7/2162\" title=\"picture 9\">",
"      Bullae caused by Fusarium spp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/6/12386\" title=\"picture 10\">",
"      Skin lesions of disseminated fusariosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/32/36352\" title=\"picture 11\">",
"      Multiple cutaneous fusarial skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/6/25701\" title=\"picture 12\">",
"      Fusarium macroconidia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/27/7602\" title=\"picture 13\">",
"      F solani microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/16/20738\" title=\"picture 14\">",
"      Fusarium hyphae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/33/24080\" title=\"picture 15\">",
"      Fusarium hematoxylin and eosin stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16218|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/5/8285\" title=\"table 1\">",
"      Clinical spectrum of fusariosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=related_link\">",
"      Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_29_10713="Genetics of asthma";
var content_f10_29_10713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics of asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10713/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10713/contributors\">",
"     Kathleen C Barnes, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10713/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10713/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10713/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10713/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/29/10713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is a condition that likely results from complex interactions between multiple genetic and environmental influences. Studies of twins and of families of asthmatic individuals have shown that asthma occurs in a pattern consistent with heritable factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. There are clearly components of the asthma phenotype that appear strongly heritable, although these inherited components do not follow the simple Mendelian pattern that is seen in monogenic disorders such as cystic fibrosis, and the specific genes responsible for these inherited components have yet to be identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link\">",
"     \"Basic principles of genetic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetics of asthma will be reviewed here; epidemiology and risk factors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19653?source=see_link\">",
"     \"Epidemiology of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"     \"Risk factors for asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISSUES IN STUDYING ASTHMA GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human and animal data currently suggest that the syndrome of asthma is likely transmitted by multiple genes. In addition, different genes in different individuals may lead to the same phenotype (locus heterogeneity), and multiple genes acting in the same individual (oligogenic or polygenic inheritance) may culminate in expression of the asthma phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some genes may influence the development of asthma, while others modify asthma severity or the patient's response to therapy. Finally, interactions between genetic factors and environmental influences provide another layer of complexity.",
"   </p>",
"   <p>",
"    Exploration of the genetics of asthma has also been hampered by the fact that there is no \"gold standard\" diagnostic test for asthma, and the clinical diagnosis is inconsistently applied. To circumvent these issues, investigators have studied the distribution of asthma-related traits, including bronchial hyperresponsiveness and measures of atopy (eg, total serum IgE levels, skin test reactivity), in addition to the presence or absence of an asthma diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETIC TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three main strategies are being employed to identify the genetic factors that predispose to the development of asthma:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Linkage analysis in families with asthma",
"     </li>",
"     <li>",
"      Case-control or family-based association studies",
"     </li>",
"     <li>",
"      Animal models of asthma traits",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Linkage analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linkage analysis includes a variety of statistical approaches designed to determine if a particular region of the genome cosegregates during meiosis with a postulated disease gene [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/7\">",
"     7",
"    </a>",
"    ]. A genome-wide linkage approach can be used for screening and followed by positional cloning, in which fine mapping is performed using additional markers in and around a locus of interest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For asthma and asthma-related traits, more than twenty linkage studies have been performed, and at least 10 regions have been identified as containing candidate genes potentially related to asthma. In addition, six novel genes have been identified using positional cloning, three of which may exert their effects within the mucosa and are associated with the bronchial epithelium. Others may impact the lung architecture or function, or interact with inflammatory cytokines.",
"   </p>",
"   <p>",
"    Unfortunately, the successful identification of candidate genes from linkage studies is limited and linkage of the implicated loci with other traits of asthma is not always possible [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dipeptidyl peptidase X",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dipeptidyl peptidase X, or DPP10, is localized on chromosome 2q14 in the Interleukin 1 (IL1) gene cluster, where four previous genome-wide linkage studies and two murine studies have reported evidence for linkage. A study in the United Kingdom sequenced the surrounding region of this locus and constructed a comprehensive, high-density, single-nucleotide polymorphism (SNP) linkage disequilibrium (LD) map [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/1\">",
"     1",
"    </a>",
"    ]. Significant associations between SNPs in DPP10 and asthma were identified in two large panels of families selected for asthma (English and German).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     ADAM33",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genome-wide linkage study in a large group of English families found evidence for linkage to chromosome 20p13 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/2\">",
"     2",
"    </a>",
"    ]. A gene encoding 'A disintegrin and metallopeptidase domain 33', or ADAM33, was identified as being significantly associated with asthma following positional cloning and genotyping of 135 polymorphisms in 23 genes. ADAM33 is part of a family of proteins that are membrane-anchored metalloproteases with diverse functions, including the shedding of cell-surface proteins such as cytokines and cytokine receptors. ADAM33 immunostaining was significantly greater in the lungs of patients with severe asthma, compared to those with mild or no asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     GPRA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first published genome-wide linkage scan in asthma suggested chromosome 7p; this finding was replicated in Finnish and Canadian families and then confirmed in West Australian families [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Positional cloning in this region identified an orphan G protein-coupled receptor named GPRA (G protein-coupled receptor for asthma susceptibility), which was significantly associated with asthma in 103 case-parent trios from Finland and replicated the association in Canadian families [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Protocadherin 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both asthma and bronchial hyperresponsiveness have been linked to chromosome 5q31-q33. Linkage analysis and fine mapping studies of that chromosome have identified the Protocadherin1 gene (PCDH1), which encodes an adhesion molecule expressed in alveolar macrophages and airway epithelial cells, as the area of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/14\">",
"     14",
"    </a>",
"    ]. In seven out of the eight populations studied, variants in the PCDH1 gene sequence were associated with increased bronchial hyperresponsiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Association studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Association studies determine the relationship between certain disease characteristics and the presence of specific forms (referred to as alleles) of a particular DNA marker [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/4\">",
"     4",
"    </a>",
"    ]. Millions of polymorphisms (ie, substitutions, deletions, insertions) have been identified in the approximately 20,000 to 25,000 genes across the 3 billion chemical base pairs that make up the human DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/15\">",
"     15",
"    </a>",
"    ]. Allelic association studies can be performed by genotyping these polymorphisms in unrelated individuals (cases versus controls) or in families of affected individuals (in which non-transmitted alleles are compared to transmitted alleles). Allelic association studies have provided additional evidence supporting the role of several candidate gene regions in asthma.",
"   </p>",
"   <p>",
"    The Genetic Association Database (GAD), a public archive of published gene-based genetic association studies available online, contains data from over 500 published genetic association studies on asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/6\">",
"     6",
"    </a>",
"    ]. Reviews of asthma association studies have identified 25 genes that have been associated with asthma or an associated phenotype, and have been replicated in six or more populations, with an additional 54 genes associated in two to five populations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/7,16\">",
"     7,16",
"    </a>",
"    ]. Many of the DNA markers that have been used in linkage and association studies are of uncertain functional significance, although genetic variants with known in vitro biochemical effects have also been examined. Some of the most highly replicated genes (and in some cases, functional variants) are:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Filaggrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two loss-of-function null mutations R501X and 2282del4 in the epithelial barrier gene, filaggrin (FLG), represent the most replicated genetic risk factors for atopic dermatitis (AD). Association studies suggest that filaggrin may also be asthma-related [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/17\">",
"     17",
"    </a>",
"    ]; however, distinguishing associations of FLG variants with asthma from susceptibility to AD or severity of diseases associated with AD has been challenging and remains unresolved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     ORMDL3",
"    </span>",
"    &nbsp;&mdash;&nbsp;ORMDL3, which encodes a transmembrane protein linked to the endoplasmic reticulum, lies in a cluster of genes on chromosome 17q",
"    <span class=\"nowrap\">",
"     (ZPBP2/GSDMB/ORMDL3).",
"    </span>",
"    The first asthma genome wide association study (GWAS) showed a reproducible association between childhood onset asthma and markers in this locus (p &lt;10[-12]) among European populations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/19\">",
"     19",
"    </a>",
"    ]. This association has been widely replicated in several European ancestry samples [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/20-27\">",
"     20-27",
"    </a>",
"    ], as well as Asians [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/27-29\">",
"     27-29",
"    </a>",
"    ] and Hispanics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/20,30\">",
"     20,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Beta-2 adrenergic receptor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene encoding the beta-2 adrenergic receptor (ADRB2) is situated on chromosome 5q31 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/31\">",
"     31",
"    </a>",
"    ]. The protein is a member of the large family of G-protein coupled, seven transmembrane-spanning domain receptors. It is expressed on a variety of cell types in the lung, including airway smooth muscle and epithelial cells, vascular endothelium, and inflammatory cells such as mast cells, eosinophils, and lymphocytes.",
"   </p>",
"   <p>",
"    Genetic variations in the beta-2 adrenergic receptor gene are associated with differential in vivo airway hyperresponsiveness and in vitro responses to beta agonist stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. As examples, individuals who are homozygous for the Gly16 form of the beta-2 adrenergic receptor gene have attenuated responses and more rapid tachyphylaxis to adrenergic bronchodilator medications than do those with the wild type, homozygous Arg16 form of the gene [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of identified beta-2 adrenergic receptor polymorphisms remains unclear. There is evidence for beta-2 adrenergic receptor dysfunction in nocturnal asthma, and polymorphic forms of the receptor are associated with IgE variability; however, polymorphisms do",
"    <strong>",
"     NOT",
"    </strong>",
"    increase the risk of developing asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/35,37-39\">",
"     35,37-39",
"    </a>",
"    ]. Further study may clarify the precise role of beta receptor dysfunction in the genesis and course of asthma. At present, beta-2 adrenergic receptor polymorphisms cannot explain the presence or absence of clinical asthma, nor can these polymorphisms be used as reliable predictors of clinical response to beta-2 agonist therapy for asthma management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link\">",
"     \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Interleukin-4 receptor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case-control study reported an association between a polymorphic variant in the interleukin-4 (IL-4) receptor and atopy",
"    <span class=\"nowrap\">",
"     (-589C/T),",
"    </span>",
"    which was defined as an elevated level of total or specific IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/40\">",
"     40",
"    </a>",
"    ]. In vitro studies demonstrated that peripheral blood mononuclear cells from individuals heterozygous for the mutant allele had a two-fold elevation in the expression of CD23 (the low affinity IgE receptor) in response to IL-4, while individuals homozygous for the mutant allele had a three-fold elevation in CD23 expression in response to IL-4. These results have been extensively replicated in other populations and in family-based association studies (which are not susceptible to false positive associations based upon population stratification) both for asthma and for associated phenotypes such as elevated total serum IgE and forced expiratory volume in one second (FEV1) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/9,41-47\">",
"     9,41-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis of asthma\", section on 'Th2 lymphocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the human leukocyte antigen G (HLAG) genes and the gene encoding the high affinity IgE receptor (FCepsilonR1B) identified through positional cloning have been associated with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/7\">",
"     7",
"    </a>",
"    ]. However, other studies have failed to replicate these associations, raising doubt regarding their generalizability to the population at large or eventual utility for diagnostic or prognostic applications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/7,16\">",
"     7,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A functional polymorphism in the promoter region of the CD14 gene, which encodes the receptor for lipopolysaccharide and plays a role in innate immunity, may influence the risk for atopy and severity of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/4,8,48-56\">",
"     4,8,48-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genome-wide association studies (GWAS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major limitation in the candidate gene approach is that selection of candidates is often based on limited knowledge, and each potentially causal variant at each candidate gene can only make a modest contribution to overall heritability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/57\">",
"     57",
"    </a>",
"    ]. Data from the HapMap Project (",
"    <a class=\"external\" href=\"file://www.hapmap.org/\">",
"     www.hapmap.org",
"    </a>",
"    ), combined with more accurate approaches to select tagging markers sufficiently dense to capture most of the common variation in the human genome, have allowed genome-wide association studies (GWAS) to replace candidate gene studies as an unbiased approach to search for genes controlling risk to complex diseases, like asthma.",
"   </p>",
"   <p>",
"    Nearly a dozen GWAS have reported associations with asthma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its associated phenotypes; however, these have been performed primarily using European ancestry populations as the discovery population, with very limited replication in non-European groups [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/19,58-66\">",
"     19,58-66",
"    </a>",
"    ]. Several of these studies are described below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first asthma GWAS showed a reproducible association between childhood onset asthma and markers near the ORMDL3 gene on chromosome 17q21 (p&lt;10[-12]) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'ORMDL3'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The second GWAS on asthma found an association between a promoter variant in the chitinase 3-like 1 (CHI3L1) gene encoding YKL-40 and asthma, bronchial hyperresponsiveness (BHR), and reduced lung function [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/58,63\">",
"       58,63",
"      </a>",
"      ]. The CH13L1 variant was most strongly associated with elevated serum YKL-40 levels (p=1.1x10 [-13]), suggesting YKL-40 may be a reliable biomarker for asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using the GWAS approach, an association has also been observed between functional variants in the gene encoding the alpha chain of the high affinity receptor for IgE (FCER1A) and the associated trait, total serum IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A locus on chromosome 1q31.3 containing the gene DENND1B has been associated with susceptibility to asthma based on GWAS studies in North American children of European ancestry and replicated in children of African ancestry [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/60\">",
"       60",
"      </a>",
"      ]. DENND1B is expressed in natural killer cells and dendritic cells and encodes a protein that interacts with the tumor necrosis factor alpha.",
"     </li>",
"     <li>",
"      In a GWAS study of 10,365 individuals with physician-diagnosed asthma and 16,110 unaffected individuals, associations were noted with loci on chromosome 2 (implicating",
"      <span class=\"nowrap\">",
"       IL1R/IL18R1),",
"      </span>",
"      chromosome 6 (implicating HLA-DQ), chromosome 9 (implicating interleukin 33 [IL33]), chromosome 15 (in SMAD3), and chromosome 22 (in the interleukin2 receptor subunit beta [IL2RB]) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/26\">",
"       26",
"      </a>",
"      ]. Association with the ORMDL3 locus on chromosome 17q21 was specific to childhood onset disease, as in other studies. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'ORMDL3'",
"      </a>",
"      above.) Loci strongly associated with the serum total IgE level were not associated with asthma.",
"     </li>",
"     <li>",
"      In a meta-analysis of a GWAS of ethnically diverse North American populations, four previously reported susceptibility loci were replicated (on 17q21 near IL1RL1, thymic stromal lymphopoietin [",
"      <em>",
"       TSLP",
"      </em>",
"      ], and IL33), and a new locus found at PYHIN1 (an interferon-inducible protein), specific to individuals of African descent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An Australian GWAS combined with data from a European consortium found an association between asthma risk and the interleukin receptor (IL6R) and also a gene known as leucine rich repeat containing 32 (LRRC32, or GARP) for a T regulatory cell membrane protein that is a receptor for TGF beta [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/65\">",
"       65",
"      </a>",
"      ]. A variant in the IL6R gene (rs4129267) appeared to be contributory.",
"     </li>",
"     <li>",
"      A GWAS performed in Japanese adults with asthma identified three new loci with the most significant association at rs404860 in the major histocompatibility complex (MHC) region, which is near another SNP previously associated with lung function [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using a different approach, a GWAS was used to assess whether a genetic variant might explain the variability in the responsiveness to inhaled glucocorticoids among patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/68\">",
"     68",
"    </a>",
"    ]. Among subjects in the Childhood Asthma Management Program, an association was found between SNPs in the gene for glucocorticoid-induced transcript 1 (GLCCI1) and response to inhaled glucocorticoids. The clinical effect of the SNP was small: the increase in forced expiratory volume in 1 second in the treated subjects who were homozygous for the mutant allele was only about one third of that seen in similarly treated subjects who were homozygous for the wild-type allele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain animal models of asthma either naturally manifest an asthma phenotype or can be manipulated to express certain aspects of asthma. Data for linkage analysis are obtained by examining the phenotypic expression of asthma traits in animals bred from two progenitor strains that differ substantially in expression of this trait. Various murine strains have been employed most commonly as mammalian models of asthma-related traits.",
"   </p>",
"   <p>",
"    One study examined the variation in airway responsiveness to infused",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    among various inbred mouse strains [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/13\">",
"     13",
"    </a>",
"    ]. Linkage analysis performed with the progeny of crosses between a highly responsive strain and a relatively unresponsive strain identified three regions of the mouse genome linked to the phenotypic trait of airway hyperresponsiveness. However, no specific genetic determinants have yet been identified with such animal models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ETHNIC DIVERSITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of asthma genetics have not adequately sampled the diverse human populations afflicted with asthma. One review revealed that genetic studies in white populations (ie, of northern and western European ancestry) represented 60 percent of the association studies reported from 1987 to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/7\">",
"     7",
"    </a>",
"    ]; conversely, there were only 25 studies (3 percent) of African-based populations and 41 studies of Hispanic populations. These minority populations are clearly under represented, despite the fact that they suffer disproportionately from asthma morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/40,69,70\">",
"     40,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain allelic variants in allergic response candidate genes are more common in people of non-European descent. Also, the 'wild type' allele, rather than the variant, confers risk of the trait in some cases. As an example, the functional variant T allele at position -260 in the CD14 gene has been associated with lower total IgE levels and less severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/4,8,48-51,54\">",
"     4,8,48-51,54",
"    </a>",
"    ]. In contrast, a functional polymorphism leading to lack of expression of Duffy",
"    <span class=\"nowrap\">",
"     antigen/receptor",
"    </span>",
"    for chemokines (DARC) appears to increase susceptibility to asthma and atopy among certain populations of African descent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Replication of GWAS findings in non-European groups has been limited, supporting the notion that certain genes (or polymorphisms in those genes) may be unique to different ethnic groups. For example, as described above, associations in single nucleotide polymorphisms (SNPs) near the ORMDL3 gene reported in the first asthma GWAS have been widely replicated in several ethnically diverse populations. However, the SNPs significantly associated in the discovery population (European), and replicated by other groups, were not significantly associated with asthma in several independent African-American populations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/20,24,72\">",
"     20,24,72",
"    </a>",
"    ]. These studies suggest that polymorphisms may explain, at least in part, the marked disparities observed in risk for allergic asthma in certain populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     GENE-ENVIRONMENT INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concordance rates for atopy among monozygotic twins raised together are only 50 to 60 percent, suggesting that differences in exposure to certain environmental triggers may account for some of the disparity of disease expression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/73\">",
"     73",
"    </a>",
"    ]. In a study of asthma and allergic rhinitis among 3808 pairs of Australian twins, about 40 percent of the genetic liability for both diseases was due to environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/74\">",
"     74",
"    </a>",
"    ]. Elsewhere, it has been demonstrated that genes and the environment contribute approximately equally to asthma and associated traits such as total IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/75\">",
"     75",
"    </a>",
"    ]. The marked increase in asthma prevalence over the past century supports the role of unknown environmental factors.",
"   </p>",
"   <p>",
"    Added to the complexity is the observation that associations with alleles at candidate genes and interactions between these genes might only be observed among certain subpopulations with nearly identical environmental and genetic backgrounds. As an example, an association between the CD14(-260)C&gt;T variant and low total IgE was noted in school children living in",
"    <span class=\"nowrap\">",
"     urban/suburban",
"    </span>",
"    Tucson, AZ; however, the opposite association was reported in a farming community [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/4,76\">",
"     4,76",
"    </a>",
"    ]. In other studies, the association of asthma with CD14(-260)C&gt;T was influenced by pet exposure, the dose of endotoxin in the domestic environment, or country living [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/8,77,78\">",
"     8,77,78",
"    </a>",
"    ], suggesting that the unusual role that endotoxin exposure plays in asthma may be due to a unique combination of susceptibility genes and the degree of exposure to endotoxin.",
"   </p>",
"   <p>",
"    Environmental tobacco exposure has also been shown to affect the extent to which significant associations are observed between candidate gene variants and asthma and atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/52,77,79,80\">",
"     52,77,79,80",
"    </a>",
"    ]. The interaction of early life tobacco smoke exposure and certain genetic variants to increase asthma risk was demonstrated in a study of 372 families with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/22\">",
"     22",
"    </a>",
"    ]. Certain single nucleotide polymorphisms (SNPs) in the 17q21 region increased the risk of early-onset asthma and this risk was further increased by early life tobacco smoke exposure.",
"   </p>",
"   <p>",
"    Certain single nucleotide polymorphisms (SNPs) in the transforming growth factor-beta (TGF-beta) gene were associated with increased airway responsiveness and increased asthma exacerbation rates in cohorts of Costa Rican and non-Hispanic white children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/81\">",
"     81",
"    </a>",
"    ]. In this study, high dust mite exposure further increased the likelihood of asthma exacerbations among patients with alleles of two SNPs (rs2241712 and rs1800471).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16001407\">",
"    <span class=\"h1\">",
"     EPIGENETICS AND THE INHERITANCE OF ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epigenetics (chemical reactions that switch parts of the genome on and off) is thought to be one of the mechanisms by which the environment interacts with the genome to cause changes in gene expression (ie, heritable changes in gene expression due to non-coding changes to the DNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. As an example, DNA methylation, a covalent (reversible) modification of DNA in which a methyl group is transferred from S-adenosylmethionine to cytosine residues at cytosine-guanine (CG) dinucleotides by DNA-methyltransferases, is associated with reduced gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several observations suggest epigenetics may be involved in pathogenesis of asthma. First, the concordance rate in monozygotic twins of only approximately50 percent argues for non-genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/73,85\">",
"     73,85",
"    </a>",
"    ]. Second, complex gene-environment interactions are involved in asthma, which could reflect epigenetic genome modifications. Interactions have been observed between maternal smoking during pregnancy and markers, such as interleukin-1 receptor antagonist (IL1RN) with a significant increase in risk of asthma in offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/86\">",
"     86",
"    </a>",
"    ]. Conversely, in utero exposure to rural environments (ie, endotoxin exposure) seems to have protective effects against the development of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Third, sex-specific differences exist, where the prevalence of asthma is higher in boys during prepuberty, but highest among girls after puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/89\">",
"     89",
"    </a>",
"    ]. Also, a parent-of-origin effect exists in susceptibility to asthma and elevated total serum IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/90\">",
"     90",
"    </a>",
"    ] with a clear difference in risk to offspring of asthmatic mothers compared to asthmatic fathers, raising the possibility that imprinted genes may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/91-95\">",
"     91-95",
"    </a>",
"    ]. Finally, a number of genetic studies of asthma have reported linkage and association in clusters of related genes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/96\">",
"     96",
"    </a>",
"    ], which suggests a higher order, epigenetic level of gene regulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FUTURE STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;SNPs have been considered to be the most common (approximately 10 million distinct SNPs) among all possible forms of genetic variation in the human genome (ie, 10 or more types of DNA variants) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. However, advancements in array-based comparative genomic hybridization (CGH) and high-density oligonucleotide microarray technologies have provided evidence of duplications in genomic sequences, also known as copy number variants (CNV). Representing deletions and duplications of DNA segments ranging in size from 1,000 bases (1 kb) to 3 Mb, CNVs occur at relatively high frequencies in human populations and may cover at least 2 percent of the genome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/99-102\">",
"     99-102",
"    </a>",
"    ]. In the context of nucleotide coverage, CNVs likely affect more of the human genome than SNPs.",
"   </p>",
"   <p>",
"    The relevance of CNVs in asthma is evident from associations between the 15-kb deletion spanning the GSTM1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/103,104\">",
"     103,104",
"    </a>",
"    ] and other deletion polymorphisms in the angiotensin converting enzyme (ACE) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. With the placement of CNVs on high-throughput genotyping platforms, including GWAS platforms, it is anticipated that more associations will be forthcoming.",
"   </p>",
"   <p>",
"    Another promising technique is to combine genome-wide association SNP data with genome-wide expression data; this allows examination of differentially expressed genes as quantitative phenotypes, referred to as \"genetical genomics\". Large numbers of genotypes, provided by genotyping microarrays such as those used in GWAS, are then combined with linkage analysis to locate areas of the genome controlling gene expression. Expression quantitative trait loci (eQTL) are identified as markers associated with gene expression. Cis and trans-acting expression eQTLs can be classified based on the location of the mRNA transcript compared to the eQTL that influences expression of the transcript. An eQTL in the same bin (or region) as the transcript is classified as cis-acting, and an eQTL in a different bin as trans-acting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/107\">",
"     107",
"    </a>",
"    ]. By using this eQTL approach, it is possible to determine the extent of variation in gene expression close to the genes that show genetic variation. As an example, the validity of the GWAS findings regarding ORMDL3 was confirmed using eQTL; markers associated with asthma were also strongly associated (P&lt;10(-22)) in cis with transcript levels of ORMDL3 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10713/abstract/19,108\">",
"     19,108",
"    </a>",
"    ]. This is the first demonstration of eQTL for asthma genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is a syndrome that is passed down through families in complex patterns. There are clearly components of the asthma phenotype that are heritable, although the genes responsible for these inherited components have yet to be identified. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma may arise from different genes in different individuals leading to the same phenotype, multiple genes acting in the same individual to produce the phenotype, and complex interactions between environmental factors and a patient's underlying genetics. In addition, there may be asthma pathogenesis genes, asthma severity modifying genes, and asthma treatment modifying genes. The role of epigenetic mechanisms in the pathogenesis of asthma has not been widely studied, but several observations suggest that epigenetics is likely to be involved. The study of asthma genetics is further complicated by the lack of a \"gold standard\" diagnostic test for asthma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Issues in studying asthma genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three main strategies currently used to identify the genetic factors that predispose to the development of asthma are linkage analysis in families with asthma, case-control or family-based association studies, and animal models of asthma traits. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetic techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Linkage analysis is a statistical technique used to identify regions of the genome that cosegregate during meiosis with a postulated disease gene. A small number of candidate genes of uncertain function have been identified by linkage analysis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Linkage analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Association studies determine the relationship between certain disease characteristics and the presence of specific alleles of a particular DNA marker. Using this technique, genes that encode the beta-2 adrenergic receptor (ADR2) and the interleukin-4 (IL-4) receptor have been identified as possibly important. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Association studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain groups of people, such as African-based and Hispanic populations, have been underrepresented in asthma genetics research, despite the fact that they suffer disproportionately from asthma morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Ethnic diversity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite recent advances in the identification of asthma-related genetic variation, at present there is no established clinical utility for these findings.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/1\">",
"      Allen M, Heinzmann A, Noguchi E, et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet 2003; 35:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/2\">",
"      Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/3\">",
"      Laitinen T, Polvi A, Rydman P, et al. Characterization of a common susceptibility locus for asthma-related traits. Science 2004; 304:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/4\">",
"      Baldini M, Lohman IC, Halonen M, et al. A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/5\">",
"      Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291:1304.",
"     </a>",
"    </li>",
"    <li>",
"     Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat Genet 2004; 36:431. Available on-line at file://geneticassociationdb.nih.gov.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/7\">",
"      Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun 2006; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/8\">",
"      Zambelli-Weiner A, Ehrlich E, Stockton ML, et al. Evaluation of the CD14/-260 polymorphism and house dust endotoxin exposure in the Barbados Asthma Genetics Study. J Allergy Clin Immunol 2005; 115:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/9\">",
"      Walley AJ, Cookson WO. Investigation of an interleukin-4 promoter polymorphism for associations with asthma and atopy. J Med Genet 1996; 33:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/10\">",
"      Foley SC, Mogas AK, Olivenstein R, et al. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J Allergy Clin Immunol 2007; 119:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/11\">",
"      Daniels SE, Bhattacharrya S, James A, et al. A genome-wide search for quantitative trait loci underlying asthma. Nature 1996; 383:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/12\">",
"      Laitinen T, Daly MJ, Rioux JD, et al. A susceptibility locus for asthma-related traits on chromosome 7 revealed by genome-wide scan in a founder population. Nat Genet 2001; 28:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/13\">",
"      Leaves NI, Bhattacharyya S, Wiltshire S, Cookson WO. A detailed genetic map of the chromosome 7 bronchial hyper-responsiveness locus. Eur J Hum Genet 2002; 10:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/14\">",
"      Koppelman GH, Meyers DA, Howard TD, et al. Identification of PCDH1 as a novel susceptibility gene for bronchial hyperresponsiveness. Am J Respir Crit Care Med 2009; 180:929.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ornl.gov/sci/techresources/Human_Genome/home.shtml (Accessed on May 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/16\">",
"      Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 2008; 8:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/17\">",
"      Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/18\">",
"      Rogers AJ, Celed&oacute;n JC, Lasky-Su JA, et al. Filaggrin mutations confer susceptibility to atopic dermatitis but not to asthma. J Allergy Clin Immunol 2007; 120:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/19\">",
"      Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/20\">",
"      Galanter J, Choudhry S, Eng C, et al. ORMDL3 gene is associated with asthma in three ethnically diverse populations. Am J Respir Crit Care Med 2008; 177:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/21\">",
"      Bisgaard H, B&oslash;nnelykke K, Sleiman PM, et al. Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med 2009; 179:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/22\">",
"      Bouzigon E, Corda E, Aschard H, et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. N Engl J Med 2008; 359:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/23\">",
"      Madore AM, Tremblay K, Hudson TJ, Laprise C. Replication of an association between 17q21 SNPs and asthma in a French-Canadian familial collection. Hum Genet 2008; 123:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/24\">",
"      Sleiman PM, Annaiah K, Imielinski M, et al. ORMDL3 variants associated with asthma susceptibility in North Americans of European ancestry. J Allergy Clin Immunol 2008; 122:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/25\">",
"      Tavendale R, Macgregor DF, Mukhopadhyay S, Palmer CN. A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications. J Allergy Clin Immunol 2008; 121:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/26\">",
"      Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/27\">",
"      Halapi E, Gudbjartsson DF, Jonsdottir GM, et al. A sequence variant on 17q21 is associated with age at onset and severity of asthma. Eur J Hum Genet 2010; 18:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/28\">",
"      Hirota T, Harada M, Sakashita M, et al. Genetic polymorphism regulating ORM1-like 3 (Saccharomyces cerevisiae) expression is associated with childhood atopic asthma in a Japanese population. J Allergy Clin Immunol 2008; 121:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/29\">",
"      Leung TF, Sy HY, Ng MC, et al. Asthma and atopy are associated with chromosome 17q21 markers in Chinese children. Allergy 2009; 64:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/30\">",
"      Wu H, Romieu I, Sienra-Monge JJ, et al. Genetic variation in ORM1-like 3 (ORMDL3) and gasdermin-like (GSDML) and childhood asthma. Allergy 2009; 64:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/31\">",
"      Kobilka BK, Dixon RA, Frielle T, et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A 1987; 84:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/32\">",
"      Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97:10483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/33\">",
"      Green SA, Turki J, Bejarano P, et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/34\">",
"      Ramsay CE, Hayden CM, Tiller KJ, et al. Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway responsiveness. Clin Exp Allergy 1999; 29:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/35\">",
"      Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/36\">",
"      Tan S, Hall IP, Dewar J, et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/37\">",
"      Turki J, Pak J, Green SA, et al. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995; 95:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/38\">",
"      Hall IP, Blakey JD, Al Balushi KA, et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 2006; 368:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/39\">",
"      Dewar JC, Wilkinson J, Wheatley A, et al. The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997; 100:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/40\">",
"      Joseph CL, Williams LK, Ownby DR, et al. Applying epidemiologic concepts of primary, secondary, and tertiary prevention to the elimination of racial disparities in asthma. J Allergy Clin Immunol 2006; 117:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/41\">",
"      Burchard EG, Silverman EK, Rosenwasser LJ, et al. Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med 1999; 160:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/42\">",
"      Zhu S, Chan-Yeung M, Becker AB, et al. Polymorphisms of the IL-4, TNF-alpha, and Fcepsilon RIbeta genes and the risk of allergic disorders in at-risk infants. Am J Respir Crit Care Med 2000; 161:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/43\">",
"      Sandford AJ, Chagani T, Zhu S, et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000; 106:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/44\">",
"      Begh&eacute; B, Barton S, Rorke S, et al. Polymorphisms in the interleukin-4 and interleukin-4 receptor alpha chain genes confer susceptibility to asthma and atopy in a Caucasian population. Clin Exp Allergy 2003; 33:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/45\">",
"      Kabesch M, Tzotcheva I, Carr D, et al. A complete screening of the IL4 gene: novel polymorphisms and their association with asthma and IgE in childhood. J Allergy Clin Immunol 2003; 112:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/46\">",
"      Basehore MJ, Howard TD, Lange LA, et al. A comprehensive evaluation of IL4 variants in ethnically diverse populations: association of total serum IgE levels and asthma in white subjects. J Allergy Clin Immunol 2004; 114:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/47\">",
"      Noguchi E, Shibasaki M, Arinami T, et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy 1998; 28:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/48\">",
"      Gao PS, Mao XQ, Baldini M, et al. Serum total IgE levels and CD14 on chromosome 5q31. Clin Genet 1999; 56:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/49\">",
"      Leung TF, Tang NL, Sung YM, et al. The C-159T polymorphism in the CD14 promoter is associated with serum total IgE concentration in atopic Chinese children. Pediatr Allergy Immunol 2003; 14:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/50\">",
"      Koppelman GH, Reijmerink NE, Colin Stine O, et al. Association of a promoter polymorphism of the CD14 gene and atopy. Am J Respir Crit Care Med 2001; 163:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/51\">",
"      Buckov&aacute; D, Holl&aacute; LI, Sch&uuml;ller M, et al. Two CD14 promoter polymorphisms and atopic phenotypes in Czech patients with IgE-mediated allergy. Allergy 2003; 58:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/52\">",
"      Choudhry S, Avila PC, Nazario S, et al. CD14 tobacco gene-environment interaction modifies asthma severity and immunoglobulin E levels in Latinos with asthma. Am J Respir Crit Care Med 2005; 172:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/53\">",
"      Sa&ccedil;kesen C, Karaaslan C, Keskin O, et al. The effect of polymorphisms at the CD14 promoter and the TLR4 gene on asthma phenotypes in Turkish children with asthma. Allergy 2005; 60:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/54\">",
"      Woo JG, Assa'ad A, Heizer AB, et al. The -159 C--&gt;T polymorphism of CD14 is associated with nonatopic asthma and food allergy. J Allergy Clin Immunol 2003; 112:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/55\">",
"      Sharma M, Batra J, Mabalirajan U, et al. Suggestive evidence of association of C-159T functional polymorphism of the CD14 gene with atopic asthma in northern and northwestern Indian populations. Immunogenetics 2004; 56:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/56\">",
"      Martin AC, Laing IA, Khoo SK, et al. Acute asthma in children: Relationships among CD14 and CC16 genotypes, plasma levels, and severity. Am J Respir Crit Care Med 2006; 173:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/57\">",
"      Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005; 6:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/58\">",
"      Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008; 358:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/59\">",
"      Weidinger S, Gieger C, Rodriguez E, et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. PLoS Genet 2008; 4:e1000166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/60\">",
"      Sleiman PM, Flory J, Imielinski M, et al. Variants of DENND1B associated with asthma in children. N Engl J Med 2010; 362:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/61\">",
"      Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009; 41:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/62\">",
"      Hancock DB, Romieu I, Shi M, et al. Genome-wide association study implicates chromosome 9q21.31 as a susceptibility locus for asthma in mexican children. PLoS Genet 2009; 5:e1000623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/63\">",
"      Himes BE, Hunninghake GM, Baurley JW, et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet 2009; 84:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/64\">",
"      Hirota T, Takahashi A, Kubo M, et al. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. Nat Genet 2011; 43:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/65\">",
"      Ferreira MA, Matheson MC, Duffy DL, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet 2011; 378:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/66\">",
"      Lasky-Su J, Himes BE, Raby BA, et al. HLA-DQ strikes again: genome-wide association study further confirms HLA-DQ in the diagnosis of asthma among adults. Clin Exp Allergy 2012; 42:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/67\">",
"      Torgerson DG, Ampleford EJ, Chiu GY, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet 2011; 43:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/68\">",
"      Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011; 365:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/69\">",
"      Carter-Pokras OD, Gergen PJ. Reported asthma among Puerto Rican, Mexican-American, and Cuban children, 1982 through 1984. Am J Public Health 1993; 83:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/70\">",
"      Homa DM, Mannino DM, Lara M. Asthma mortality in U.S. Hispanics of Mexican, Puerto Rican, and Cuban heritage, 1990-1995. Am J Respir Crit Care Med 2000; 161:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/71\">",
"      Vergara C, Tsai YJ, Grant AV, et al. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. Am J Respir Crit Care Med 2008; 178:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/72\">",
"      Mathias RA, Grant AV, Rafaels N, et al. A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol 2010; 125:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/73\">",
"      Marsh DG, Meyers DA, Bias WB. The epidemiology and genetics of atopic allergy. N Engl J Med 1981; 305:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/74\">",
"      Duffy DL, Martin NG, Battistutta D, et al. Genetics of asthma and hay fever in Australian twins. Am Rev Respir Dis 1990; 142:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/75\">",
"      Palmer LJ, Burton PR, James AL, et al. Familial aggregation and heritability of asthma-associated quantitative traits in a population-based sample of nuclear families. Eur J Hum Genet 2000; 8:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/76\">",
"      Ober, C, Tselenko, A, Cox, NJ. Searching for asthma and atopy genes in the Hutterites: Genome-wide studies using linkage and association. Am J Respir Crit Care Med 2000; 161:A600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/77\">",
"      Bottema RW, Reijmerink NE, Kerkhof M, et al. Interleukin 13, CD14, pet and tobacco smoke influence atopy in three Dutch cohorts: the allergenic study. Eur Respir J 2008; 32:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/78\">",
"      Smit LA, Siroux V, Bouzigon E, et al. CD14 and toll-like receptor gene polymorphisms, country living, and asthma in adults. Am J Respir Crit Care Med 2009; 179:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/79\">",
"      Colilla S, Nicolae D, Pluzhnikov A, et al. Evidence for gene-environment interactions in a linkage study of asthma and smoking exposure. J Allergy Clin Immunol 2003; 111:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/80\">",
"      Meyers DA, Postma DS, Stine OC, et al. Genome screen for asthma and bronchial hyperresponsiveness: interactions with passive smoke exposure. J Allergy Clin Immunol 2005; 115:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/81\">",
"      Sharma S, Raby BA, Hunninghake GM, et al. Variants in TGFB1, dust mite exposure, and disease severity in children with asthma. Am J Respir Crit Care Med 2009; 179:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/82\">",
"      Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/83\">",
"      Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/84\">",
"      Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010; 11:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/85\">",
"      Nystad W, R&oslash;ysamb E, Magnus P, et al. A comparison of genetic and environmental variance structures for asthma, hay fever and eczema with symptoms of the same diseases: a study of Norwegian twins. Int J Epidemiol 2005; 34:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/86\">",
"      Ramadas RA, Sadeghnejad A, Karmaus W, et al. Interleukin-1R antagonist gene and pre-natal smoke exposure are associated with childhood asthma. Eur Respir J 2007; 29:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/87\">",
"      Ege MJ, Herzum I, B&uuml;chele G, et al. Prenatal exposure to a farm environment modifies atopic sensitization at birth. J Allergy Clin Immunol 2008; 122:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/88\">",
"      Douwes J, Cheng S, Travier N, et al. Farm exposure in utero may protect against asthma, hay fever and eczema. Eur Respir J 2008; 32:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/89\">",
"      Weiss ST, Gold DR. Gender differences in asthma. Pediatr Pulmonol 1995; 19:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/90\">",
"      Traherne JA, Hill MR, Hysi P, et al. LD mapping of maternally and non-maternally derived alleles and atopy in FcepsilonRI-beta. Hum Mol Genet 2003; 12:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/91\">",
"      Litonjua AA, Carey VJ, Burge HA, et al. Parental history and the risk for childhood asthma. Does mother confer more risk than father? Am J Respir Crit Care Med 1998; 158:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/92\">",
"      Cookson WO, Young RP, Sandford AJ, et al. Maternal inheritance of atopic IgE responsiveness on chromosome 11q. Lancet 1992; 340:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/93\">",
"      Sears MR, Holdaway MD, Flannery EM, et al. Parental and neonatal risk factors for atopy, airway hyper-responsiveness, and asthma. Arch Dis Child 1996; 75:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/94\">",
"      Lin H, Mosmann TR, Guilbert L, et al. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 1993; 151:4562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/95\">",
"      Nicolae D, Cox NJ, Lester LA, et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet 2005; 76:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/96\">",
"      Barnes KC. Genetic studies of the etiology of asthma. Proc Am Thorac Soc 2011; 8:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/97\">",
"      Feuk L, Marshall CR, Wintle RF, Scherer SW. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet 2006; 15 Spec No 1:R57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/98\">",
"      International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/99\">",
"      Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet 2004; 36:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/100\">",
"      Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science 2004; 305:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/101\">",
"      Tuzun E, Sharp AJ, Bailey JA, et al. Fine-scale structural variation of the human genome. Nat Genet 2005; 37:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/102\">",
"      Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006; 444:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/103\">",
"      Kabesch M, Hoefler C, Carr D, et al. Glutathione S transferase deficiency and passive smoking increase childhood asthma. Thorax 2004; 59:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/104\">",
"      Cheng SL, Yu CJ, Chen CJ, Yang PC. Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur Respir J 2004; 23:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/105\">",
"      Benessiano J, Crestani B, Mestari F, et al. High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in asthma. J Allergy Clin Immunol 1997; 99:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/106\">",
"      Busquets X, MacFarlane NG, Heine-Su&ntilde;er D, et al. Angiotensin-converting-enzyme gene polymorphisms, smoking and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007; 2:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/107\">",
"      de Koning DJ, Haley CS. Genetical genomics in humans and model organisms. Trends Genet 2005; 21:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10713/abstract/108\">",
"      Dixon AL, Liang L, Moffatt MF, et al. A genome-wide association study of global gene expression. Nat Genet 2007; 39:1202.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 561 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-BE0DD41560-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10713=[""].join("\n");
var outline_f10_29_10713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISSUES IN STUDYING ASTHMA GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETIC TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Linkage analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dipeptidyl peptidase X",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - ADAM33",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - GPRA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Protocadherin 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Association studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Filaggrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - ORMDL3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Beta-2 adrenergic receptor gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Interleukin-4 receptor gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genome-wide association studies (GWAS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ETHNIC DIVERSITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      GENE-ENVIRONMENT INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16001407\">",
"      EPIGENETICS AND THE INHERITANCE OF ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FUTURE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=related_link\">",
"      Beta-2 adrenergic receptor dysfunction and polymorphism in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19653?source=related_link\">",
"      Epidemiology of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_29_10714="Prophylaxis of infections in solid organ transplantation";
var content_f10_29_10714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prophylaxis of infections in solid organ transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10714/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10714/contributors\">",
"     Barbara D Alexander, MD, MHS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10714/contributors\">",
"     Jay A Fishman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10714/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10714/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/29/10714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/29/10714/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/29/10714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid organ transplant recipients are considered to be at \"high risk\" for developing infection; individual risk is determined by a relationship between the epidemiologic exposures of the individual and the patient's \"net state of immunosuppression\" [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/1\">",
"     1",
"    </a>",
"    ]. The successful prevention of infection in the solid organ transplant recipient requires an understanding of these factors in order to develop a preventive strategy adapted for each individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidemiologic exposures may have occurred many years before transplantation or at any point following the transplant procedure. The range of pathogens to which patients are exposed has increased as transplantation has become available to a broader range of individuals with more varied epidemiologic exposures and as transplant recipients survive longer, remaining on lifelong immunosuppression. Thus, clinicians must obtain a detailed history of encounters with potential pathogens, even if the exposure was relatively remote [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of antimicrobial agents for prophylaxis varies by the disease being targeted for prevention and the nature of the recipient's perceived risks. Strategies include universal prophylaxis and preemptive therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Universal prophylaxis involves giving an antimicrobial agent to all patients considered to be at increased risk for infection during a defined period.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) is given universally to all transplant recipients who do not have sulfa allergies. TMP-SMX is effective for the prevention of Pneumocystis pneumonia (PCP), which occurs in many United States transplantation centers at an overall rate of 10 to 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/4\">",
"       4",
"      </a>",
"      ]. It provides effective prophylaxis against other pathogens, including Listeria monocytogenes and Toxoplasma gondii. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pneumocystis pneumonia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A preemptive approach involves using sensitive assays (eg, antigen detection or molecular assays) to monitor patients at predefined intervals to detect viral replication (eg, viremia) before infection progresses to invasive disease. A positive assay triggers the initiation of antiviral therapy, a reduction in the intensity of immunosuppression,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intensified monitoring.",
"     </li>",
"     <li>",
"      With intensification of immunosuppressive therapies for transplantation, notably T cell depleting antibody induction therapies, more recipients now receive some period of antiviral prophylaxis for cytomegalovirus (CMV) following induction therapy, most often for the seropositive organ donor who receives an organ from a seronegative recipient",
"      <span class=\"nowrap\">",
"       (D+/R-)",
"      </span>",
"      or from a seropositive recipient",
"      <span class=\"nowrap\">",
"       (D+/R+).",
"      </span>",
"      Pre-emptive therapy incurs extra costs for monitoring and coordination of outpatient care as well as clinical effects of episodes of viremia, but reduces drug exposures and avoids some of the costs and toxicities of prophylactic antiviral therapy. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS PRETRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before transplantation, it is important to establish the patient's immunization history and prior infectious exposures, including travel, to design an appropriate preventative regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing for evidence of past infectious exposures is performed to detect asymptomatic infection in the transplant candidate. Some tests are recommended for all patients, while others are useful in selected patients with suggestive epidemiologic risk factors (",
"    <a class=\"graphic graphic_table graphicRef59792 \" href=\"UTD.htm?31/17/32028\">",
"     table 1",
"    </a>",
"    ). Serologic testing is used as an indicator of significant past exposures, and in some cases (eg, cytomegalovirus serostatus) the results are used to guide prophylactic strategies after transplantation. In other cases, the results are used to guide pretransplant immunizations. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation for infection before solid organ transplantation\", section on 'Laboratory testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of infection through immunization is of paramount importance to the increasing population of solid organ transplant recipients. However, many immunocompromised patients are unable to mount protective immune responses to vaccines. Furthermore, immunization with live virus vaccines may result in unchecked proliferation of attenuated vaccine strains and is therefore generally avoided in solid organ transplant recipients. For these reasons, it is optimal to immunize patients prior to transplantation. Vaccine recommendations for solid organ transplant candidates and recipients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Screening for latent TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one compilation of published cases, the incidence of tuberculosis (TB) in transplant recipients worldwide ranged from 0.35 to 15 percent, which reflected an 8- to 100-fold increased incidence over the general population in the represented countries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/3\">",
"     3",
"    </a>",
"    ]. Reactivation of latent disease following immunosuppression is thought to be the dominant factor in the pathogenesis of infection in these hosts, although transmission with the allograft, nosocomial transmission, and community-acquired tuberculosis have been documented in solid organ transplant recipients.",
"   </p>",
"   <p>",
"    Given the high morbidity and mortality associated with TB in the posttransplant setting, all patients listed for organ transplantation should undergo tuberculin skin testing (TST) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to TST, baseline chest radiographs should be obtained for anyone with epidemiologic history suggestive of possible exposure to tuberculosis. For patients with uremia, liver failure, and for those who have received corticosteroids or other immunosuppressive therapies, TST must be interpreted according to the more sensitive standards developed for patients with human immunodeficiency virus (HIV) infection.",
"   </p>",
"   <p>",
"    T cell-based interferon-gamma release assays, such as the Quantiferon Gold TB (QFT-G) assay, are a useful adjunct to TST with a high degree of concordance between TSTs and the QFT-G assay [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Although some studies have suggested that QFT-G correlates better with the risk of TB in immunocompromised patients than the TST, data remain limited [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/5\">",
"     5",
"    </a>",
"    ] and false negative results have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/7\">",
"     7",
"    </a>",
"    ]. In a study of liver transplant candidates, indeterminate QFT-G results were more likely in those with more advanced liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pretransplant anti-tuberculous prophylaxis or therapy should be provided for solid organ transplant candidates with the following specific indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tuberculin reactivity of &ge;5 mm before transplantation",
"     </li>",
"     <li>",
"      History of tuberculin reactivity without adequate prophylaxis",
"     </li>",
"     <li>",
"      Recent conversion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      to positive",
"     </li>",
"     <li>",
"      Radiographic evidence of old TB without prior prophylaxis. A chest computed tomographic (CT) scan should be performed in these patients to look for disseminated disease and to serve as a baseline study.",
"     </li>",
"     <li>",
"      History of inadequately treated TB",
"     </li>",
"     <li>",
"      Close contact with an individual with active pulmonary TB",
"     </li>",
"     <li>",
"      Receipt of an allograft from a donor with a history of untreated TB",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of infection relates to the intensity and temporal proximity of exposure. Individuals from endemic regions for TB with positive skin tests or radiologic evidence of prior disease merit therapy. Individuals with prior BCG therapy should be followed expectantly without therapy unless prior disease or recent exposure is suspected.",
"   </p>",
"   <p>",
"    If possible, therapy should be provided prior to transplantation. Patients may receive one of a variety of regimens for the treatment of latent tuberculosis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/8\">",
"     8",
"    </a>",
"    ]. The routine use of anti-TB prophylaxis after transplantation remains controversial, but is generally provided to anyone with high risk of active infection.",
"   </p>",
"   <p>",
"    Treatment after transplantation is frequently compromised by drug toxicities and interactions with immunosuppressive therapies.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     Isoniazid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    hepatotoxicity, for example, may be intolerable after liver transplantation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    will significantly reduce the serum level of calcineurin inhibitors, an effect that persists for a number of weeks after cessation of therapy. This observation suggests that therapy should be completed two to four weeks before transplantation, whenever possible. Regimens, which include the fluoroquinolones and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    , are available as alternative treatments for latent TB in organ transplant recipients.",
"   </p>",
"   <p>",
"    The evaluation and management of tuberculosis in lung transplant candidates and recipients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS PERITRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following transplantation, recipients are vulnerable to nosocomial infections, especially in the early posttransplant period. Patients with prolonged hospitalizations or who require mechanical ventilation are at particularly high risk. The infections commonly encountered in the first month after transplantation are caused by the same nosocomial pathogens that infect other complex postoperative patients. Ninety-five percent of these infections are due to bacterial and fungal agents. However, the difficulty in eradication of such infections is increased in the immunocompromised host. The unique technical features of transplantation (vascular, ureteric, tracheal, biliary anastomoses) predispose to leaks (hematoma, bile, lymphocele). Such fluid collections are a common site of infection. Individuals with chronic infections should have all organisms identified and susceptibility testing performed prior to transplantation. Active infections must be eradicated or controlled prior to transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibacterial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard surgical antibiotic prophylaxis is recommended for all organ transplant procedures. However, the choice of drug(s) can vary with the type of transplant. As an example, the risk of peritoneal soilage is great in individuals undergoing liver transplantation with Roux-en-Y biliary drainage. Other risk factors for bacterial infections after liver transplantation include large volume blood transfusions, treatment of graft rejection with corticosteroids, and CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. If the patient is colonized with vancomycin-resistant enterococcus (VRE) or Candida species, including, non-albicans strains, perioperative prophylaxis should be expanded to cover those organisms.",
"   </p>",
"   <p>",
"    Colonization with resistant gram-negative organisms poses a special hazard to patients undergoing lung transplantation since invasive infection is common. Most bacterial infections in lung transplant recipients involve the lower respiratory tract (bronchitis and pneumonia) and occur in the first two weeks posttransplant. Patients with chronic bronchiectasis and those with cystic fibrosis, who are colonized with resistant gram-negative bacteria including Pseudomonas and Burkholderia species, present a dilemma with regard to increased risk of lung transplantation. Some centers consider colonization with B. cenocepacia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/11\">",
"     11",
"    </a>",
"    ] or pan-resistant Pseudomonas species a contraindication to transplantation.",
"   </p>",
"   <p>",
"    No consensus exists for the management of patients colonized with these gram-negative organisms during the peritransplant period. Each transplant center typically develops antibiotic prophylaxis protocols based upon the susceptibility patterns of the organisms most frequently recovered at that center. Prophylactic regimens are then individualized on the basis of both recipient organisms and those isolated from the donor lungs. Serial microbiology data post-transplantation are used to refine therapy.",
"   </p>",
"   <p>",
"    Infections of ventricular assist devices and chest tubes are often due to gram-positive organisms (staphylococci, enterococci) or yeasts, which should be identified, and susceptibility testing used to guide therapy prior to and through transplantation. Drains and vascular access catheters must be removed as quickly as is feasible post-transplantation. Broad-spectrum antimicrobial prophylaxis (including antifungal agents) is generally reserved for the perioperative management of intestinal transplants since their use increases the risk of C. difficile colitis and superinfection with resistant fungal organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antifungal prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of invasive fungal infections following solid organ transplantation ranges from 5 to 42 percent and varies with the organ being transplanted. Candida and Aspergillus species are the leading causative agents, with the median time to onset following transplantation depending on the type of transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/12\">",
"     12",
"    </a>",
"    ]. These infections are associated with high overall mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/13-19\">",
"     13-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high incidence of and mortality associated with invasive mycoses in the solid organ transplant population, targeted prophylaxis for fungal infections in patients at the highest risk for such infections is reasonable. Drug interactions (especially between the azole antifungal agents and calcineurin inhibitors and rapamycin) and toxicities must be considered for each antimicrobial selection, both at initiation and cessation of therapy.",
"   </p>",
"   <p>",
"    Strategies should be developed for each institution based upon the incidence and nature of fungal infections observed. Current data support the use of prophylaxis for Aspergillus in liver and lung transplant recipients and for Candida species in liver, bowel, and pancreas transplant recipients. Given the potential for toxicities of antifungal agents and the risk for emergence of resistance, strategies for antifungal prophylaxis should not be universal but instead should be targeted toward high-risk patients and adapted to the common pathogens at each center.",
"   </p>",
"   <p>",
"    The overall efficacy of antifungal prophylaxis in solid organ transplant recipients was evaluated in a meta-analysis of 14 randomized trials with 1497 participants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/20\">",
"     20",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antifungal prophylaxis did not reduce mortality (relative risk [RR] 0.90, 95% CI 0.57-1.44).",
"     </li>",
"     <li>",
"      In liver transplant recipients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      significantly reduced invasive fungal infections (RR 0.28, 95% CI 0.13-0.57). It was estimated that 14 patients would have to be treated to prevent one infection. Although less data were available, indirect comparisons and one direct comparative trial suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      had similar efficacy.",
"     </li>",
"     <li>",
"      In renal and cardiac transplant recipients, neither",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      nor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"       clotrimazole",
"      </a>",
"      significantly reduced invasive fungal infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who should be considered for antifungal prophylaxis include those with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal and hepatic dysfunction",
"     </li>",
"     <li>",
"      Large blood transfusion requirements",
"     </li>",
"     <li>",
"      Prolonged ICU stays",
"     </li>",
"     <li>",
"      Additional surgery posttransplant including laparotomy and retransplantation",
"     </li>",
"     <li>",
"      Known fungal colonization pretransplantation",
"     </li>",
"     <li>",
"      Prior (broad-spectrum) antimicrobial use",
"     </li>",
"     <li>",
"      Prolonged use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, lung transplant recipients often receive antifungal prophylaxis because they have a relatively high risk of invasive fungal infections. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of the currently available antifungal agents is ideal for all of the indications for posttransplant prophylaxis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Choice of regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    appears to be safe and has not been associated with hepatotoxicity following liver transplantation; it can be used as prophylaxis against susceptible Candida species and reduces invasive infections in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    does not have activity against filamentous fungi. In addition, some Candida species have relative resistance (high minimum inhibitory concentrations [MICs]) to the drug. Drug interactions with calcineurin inhibitors are variable but will increase these drug levels in most patients. Similarly, serum calcineurin inhibitor levels will fall when prophylaxis is discontinued; dose readjustment is essential to prevent graft rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    capsules have poor oral bioavailability and should not be relied upon in the critically ill patient after transplantation. The itraconazole suspension has better oral bioavailability, but trials to date have failed to demonstrate the efficacy of the oral solution for the prevention of invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/22\">",
"     22",
"    </a>",
"    ]. Nevertheless, many centers use itraconazole for the prevention of fungal infection after lung transplantation despite the absence of prospective, randomized clinical trials.",
"   </p>",
"   <p>",
"    Efficacy of the intravenous formulation as prophylaxis awaits testing in clinical trials. Significant drug interactions with calcineurin inhibitors result in levels increased two- to fourfold over baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    was approved by the FDA for the treatment of aspergillosis, scedosporiosis, and fusariosis in 2002. This azole offers broader filamentous mold activity than either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , but has no activity against the agents of mucormycosis. However, no multicenter trial examining the prophylactic use of voriconazole in the solid organ transplant population has been performed to date. In addition, as with the other azoles, voriconazole is a significant inhibitor of the cytochrome P450 enzymes. Of particular note, co-administration of voriconazole and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is contraindicated due to these interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/23\">",
"     23",
"    </a>",
"    ]. Significant drug interactions with calcineurin inhibitors result in levels three- to five-fold over baseline in most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H34#H34\">",
"     \"Pharmacology of azoles\", section on 'Selected clinical effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    was approved for prophylaxis in high risk hematopoietic stem cell transplantation recipients. Its use in therapy and prophylaxis in solid organ transplantation have not yet been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    (both regular and lipid formulations) are used in a number of centers for the prevention of fungal infections. Several studies have demonstrated the failure of low-dose regimens as prophylaxis for invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], and such therapies should be used with caution.",
"   </p>",
"   <p>",
"    Limited studies evaluating aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (including a lipid formulation) for Aspergillus prophylaxis in lung transplant recipients have suggested benefit but further studies are clearly indicated to confirm efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple FDA-approved echinocandins with similar spectra of antifungal activity including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    . No trials of prophylaxis in solid organ transplantation have been performed to date. These agents are not inducers or inhibitors of the cytochrome P450 enzymes. However, in patients with mild and moderate hepatic impairment, caspofungin AUC is increased about 20 and 75 percent, respectively; there is no clinical experience with this agent in patients with severe hepatic insufficiency. Further,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    moderately increases the AUC of caspofungin and elevations in hepatic transaminases were noted in healthy subjects when the drugs were administered concomitantly. In liver transplant recipients, caspofungin may increase transaminase levels with or without coadministration of calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/29\">",
"     29",
"    </a>",
"    ]. These drugs are available in IV formulations only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antifungal prophylaxis regimens currently in use vary among institutions. The 2009 Infectious Diseases Society of America guidelines for the management of candidiasis recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 to 400 mg [3 to 6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    daily) OR",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) for at least 7 to 14 days as postoperative antifungal prophylaxis for liver, pancreas, and small bowel transplant recipients at high risk of invasive fungal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also recommend a targeted approach to antifungal prophylaxis; only high-risk patients, including those transplant recipients known to be colonized and in hospitals with high rates of invasive fungal infections, should receive antifungal prophylaxis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Patient selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Large comparative clinical trials will be needed to define optimal regimens as well as to characterize the \"high-risk\" patients most likely to benefit from prophylaxis. In endemic regions and in at-risk individuals, long-term prophylaxis may be employed to prevent the reactivation of pulmonary and extrapulmonary disease due to Coccidioides immitis, Histoplasma capsulatum, and Cryptococcus neoformans.",
"   </p>",
"   <p>",
"    The following table outlines an evidence-based approach to antifungal prophylaxis (",
"    <a class=\"graphic graphic_table graphicRef71877 \" href=\"UTD.htm?41/1/42012\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/19\">",
"     19",
"    </a>",
"    ]. Gaps in antifungal coverage should be noted for the echinocandins and azoles. Echinocandins have no activity against zygomycete molds or Cryptococcus neoformans;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , have no activity against zygomycete molds.",
"   </p>",
"   <p>",
"    Antifungal prophylaxis for lung transplant recipients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS POSTTRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After discharge from the hospital, the recipient is likely to have contacts with a variety of potential pathogens within the community. Most patients receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX; one single strength tablet per day [80 mg",
"    <span class=\"nowrap\">",
"     TMP/160",
"    </span>",
"    mg SMX] or one double strength tablet three to seven times a week) to prevent PCP and certain other infections (eg, Listeria monocytogenes, Toxoplasma gondii).",
"   </p>",
"   <p>",
"    TMP-SMX drug is active against a wide variety of opportunistic infections including Pneumocystis jirovecii, Toxoplasma gondii, and many community-acquired respiratory, gastrointestinal, and urinary tract pathogens. In addition, TMP-SMX will suppress Isospora belli (based upon experience in HIV-infected patients), and most Listeria monocytogenes and Nocardia asteroides (based upon susceptibility data). However, infections due to Nocardia species (including N. nova) have been observed in both hematopoietic stem cell and solid organ transplant recipients receiving TMP-SMX. Successful prevention of infections other than PCP requires daily dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pneumocystis pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis jirovecii (formerly P. carinii) is a ubiquitous organism and common fungus that is a well-known cause of pulmonary disease in the immunocompromised host. Prior to the use of TMP-SMX prophylaxis, the incidence of infection was reported to be as high as 70 to 88 percent in the lung transplant population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/15,31\">",
"     15,31",
"    </a>",
"    ]. The effectiveness of prophylaxis against PCP has virtually eliminated the organism as a cause of significant morbidity in solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual dose of TMP-SMX is one single tablet a day or one double-strength tablet three to seven times a week. The distinct advantages of TMP-SMX prophylaxis include low cost, low toxicity in most individuals, and efficacy in the prevention of many common urinary, respiratory, and gastrointestinal infections as well as most, but not all, infections due to Toxoplasma and Listeria species. TMP-SMX may also provide some degree of protection against infection with Nocardia spp, although breakthrough infections have been reported. As an example, in a case-control study of solid organ transplant recipients with nocardiosis, 24 (69 percent) of 35 case patients were receiving TMP-SMX for PCP prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylaxis should be continued for six months to one year. Extending the duration of PCP prophylaxis beyond one year may be warranted for lung transplant recipients, for patients receiving continued higher degrees of immunosuppression, or for those with chronic viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients allergic to sulfa-containing medications may be given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    as alternatives for PCP prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/32\">",
"     32",
"    </a>",
"    ]. Atovaquone dosage should be 1500 mg PO once daily as solid organ transplant recipients receiving lower doses have been documented to have breakthrough infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/32,35\">",
"     32,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    None of the alternative regimens is as good as daily TMP-SMX and none provides the antibacterial protection of that agent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, another agent (daily fluoroquinolone) must be added for antibacterial activity. This may be of greatest importance in renal and lung transplant recipients where the early incidence of postoperative bacterial infections is high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis is an uncommon but highly morbid infection after transplantation. Given that cysts of Toxoplasma gondii are commonly found in muscle tissues (as well as brain and phagocytic cells), the greatest risk for toxoplasmosis occurs after cardiac transplantation. The highest risk group for symptomatic reactivation disease occurs in seronegative recipients of heart transplants from seropositive donors; the risk in this group in the absence of prophylaxis is approximately 50 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/2\">",
"     2",
"    </a>",
"    ]. Toxoplasma infection presents most often as myocarditis or cardiomyopathy, but also as brain abscess, pneumonitis, empyema, or disseminated infection. Disease may occur at any time post-transplantation, with a median time to presentation of two months; up to 10 percent have reactivation in the first post-transplant month [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/37\">",
"     37",
"    </a>",
"    ]. Although uncommon, toxoplasmosis has also been transmitted by liver, kidney, and lung transplantation. Organ-transmitted disease is generally more severe than that due to reactivation of latent infection in the recipient. The risk of disease reactivation appears to be increased by use of lymphocyte-depleting induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of toxoplasmosis has not been well studied. In general, seronegative recipients of seropositive cardiac transplants receive at least 6 weeks to 6 months of prophylaxis, although lifetime prophylaxis is preferred at many centers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/39\">",
"     39",
"    </a>",
"    ]. One retrospective study suggests that TMP-SMX at a dose of one double-strength tablet three times per week is sufficient for both Pneumocystis and Toxoplasma prevention in cardiac transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/40\">",
"     40",
"    </a>",
"    ]. Other centers use lower dose regimens or add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    to TMP-SMX in high-risk recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Lower dose regimens provide less effective protection, notably in seronegative cardiac transplant recipients from seropositive donors from endemic regions (eg, France, the Caribbean islands) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/2\">",
"     2",
"    </a>",
"    ]. The risk of disease in seropositive recipients of heart transplants from seropositive donors is uncertain, but lifetime prophylaxis with at least one single-strength tablet of TMP-SMX may be beneficial.",
"   </p>",
"   <p>",
"    Most alternative regimens (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    ) have not been well studied in high-risk transplant populations. The clindamycin-pyrimethamine regimen has been used successfully in some programs as an alternative for those who are intolerant of TMP-SMX. Dapsone may also be considered in such individuals, although breakthrough infections have been observed at daily doses of 50 mg when pyrimethamine or TMP-SMX has not been included in the regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Streptococcus pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised individuals have the greatest incidence of infection due to Streptococcus pneumoniae with diminished susceptibility to penicillin; many of these isolates are also resistant to TMP-SMX in vitro. Thus, although the general population requires pneumococcal vaccination at age 55 to 65, it is generally advised that transplant candidates receive the vaccine prior to the transplant surgery unless they were vaccinated previously based upon the underlying illness, such as chronic pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=see_link&amp;anchor=H13#H13\">",
"     \"Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole\", section on 'Trimethoprim-sulfamethoxazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All solid organ transplant recipients should receive a second dose of vaccine five years after the first whether vaccination occurred before or after the transplant procedure based upon recommendations from the CDC. Whether further boosting is of advantage, as is done in asplenic patients, has not been defined in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections are among the most common complications of immune suppression after solid organ transplantation. The use of antiviral agents should be linked to the intensity of immune suppression and to the risk of the individual for disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination remains the primary method of preventing and controlling influenza and continual changes in viral antigens necessitates annual revision and administration of the influenza vaccine. The intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    should be given to solid organ transplant recipients. The intranasal live-attenuated influenza vaccine should",
"    <strong>",
"     not",
"    </strong>",
"    be given to solid organ transplant recipients since live viral vaccines are contraindicated in immunocompromised hosts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link&amp;anchor=H12#H12\">",
"     \"Immunizations in solid organ transplant candidates and recipients\", section on 'Influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiviral prophylaxis is indicated under certain circumstances, such as in solid organ transplant recipients who have been exposed to an individual with suspected or confirmed influenza infection. Specific recommendations regarding antiviral prophylaxis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) is the most common opportunistic pathogen following solid organ transplantation and is an important cause of morbidity and mortality. CMV may be acquired from the donated allograft, blood products transfused from a seropositive donor, or reactivation of endogenous virus. As a herpesvirus, CMV is both latent (once infected, always infected) and cell-associated.",
"   </p>",
"   <p>",
"    Most CMV disease occurs between one and four months after transplantation in the absence of antiviral prophylaxis. Increasingly, CMV disease is recognized in the period following cessation of prophylaxis. Patients at highest risk for CMV disease are those who are seronegative for CMV (immunologically naive) and receive an allograft from a seropositive donor",
"    <span class=\"nowrap\">",
"     (D+/R-)",
"    </span>",
"    and those with latent CMV infection who require treatment with antilymphocyte antibodies as a part of induction therapy or for graft rejection. Asymptomatic infection is common in both the",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    combination and seropositive recipients.",
"   </p>",
"   <p>",
"    The efficacy of targeted anti-CMV prophylaxis in these high-risk patients is well-documented [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A systematic review of 19 randomized controlled trials of CMV prophylaxis in 1981 solid organ transplant recipients demonstrated the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with placebo, prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      significantly reduced the risks of CMV disease (relative risk 0.42, 95 percent CI 0.34-0.52), CMV infection (relative risk 0.61, CI 0.48-0.77) and all-cause mortality (relative risk 0.63, CI 0.43-0.92). The reduction in mortality was primarily due to lower mortality from CMV disease.",
"     </li>",
"     <li>",
"      For CMV-related disease and mortality, the relative benefits of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      were consistent across recipients of heart, kidney, and liver transplants and occurred in both CMV-positive and CMV negative-recipients of seropositive organs. These results were irrespective of the type of immunosuppression that was given. No conclusions could be drawn for CMV-negative recipients of CMV-negative organs",
"      <span class=\"nowrap\">",
"       (D-/R-).",
"      </span>",
"      Patients considered at lower risk for CMV infection",
"      <span class=\"nowrap\">",
"       (D-/R-)",
"      </span>",
"      receive antiviral prophylaxis for herpes simplex virus and varicella zoster virus with acyclovir, valacyclovir, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In the subset of direct comparison treatment trials,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      was more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      and intravenous ganciclovir were as effective as oral ganciclovir.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent meta-analysis of 17 universal prophylaxis trials and 9 preemption trials demonstrated that both prophylaxis strategies were equally effective in reducing the incidence of CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/45\">",
"     45",
"    </a>",
"    ]. However, only universal prophylaxis affected patient survival and reduced graft rejection and reduced the incidence of post-transplant opportunistic infections and post-transplant lymphoproliferative disorder (PTLD) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The preferred drugs for CMV prophylaxis are IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    , although high-dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    are also effective. Issues related to CMV prophylaxis in specific transplant settings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link&amp;anchor=H15#H15\">",
"     \"Infectious complications in liver transplantation\", section on 'Cytomegalovirus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnostic techniques for CMV infection such as pp65 antigenemia assays, molecular assays (hybrid captures or PCR), and shell vial cultures with early antigen testing are used to identify transplant recipients who should receive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link&amp;anchor=H15#H15\">",
"     \"Infectious complications in liver transplantation\", section on 'Cytomegalovirus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV) is associated with posttransplant lymphoproliferative disease (PTLD). PTLD occurs in approximately 1 percent of transplants and ranges in severity from \"benign\" polyclonal lymphocytosis to highly malignant lymphomas. The optimal strategy for the prevention of PTLD has not been established, although lesser degrees of immunosuppression appear to lower the risk. Routine monitoring should be performed for higher risk patients",
"    <span class=\"nowrap\">",
"     (D+/R-",
"    </span>",
"    for EBV and all children). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Hepatitis B virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B virus vaccine",
"    </a>",
"    is recommended for all individuals prior to transplantation. Accelerated schedules for vaccination have been developed for healthy travelers but do not appear to produce an adequate immune response in transplant candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among already infected patients, hepatitis B virus (HBV) can be reactivated after transplantation. Immunosuppression can amplify HBV DNA, and steroid therapy may have a direct stimulatory effect on an enhancer region of the viral genome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. This issue is particularly important in two settings: liver transplant recipients, in whom HBV may be the cause of the primary liver disease, and renal transplant recipients, since many chronic dialysis patients are HbsAg positive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among liver transplant recipients, preventive therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"       hepatitis B immune globulin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other antiviral drugs are given to prevent reinfection of the graft. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"       \"Liver transplantation for chronic hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concerns among renal transplant recipients are deterioration of the liver and worse renal allograft survival.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      may be effective therapy in such patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link&amp;anchor=H7#H7\">",
"       \"Renal disease associated with hepatitis B virus infection\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another potential problem related to transplantation is transmission of HBV from the transplanted organ. This has occurred in hepatitis B surface antigen positive donors and in livers from donors with documented anti-HB core antibody. A review from the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database identified 23 liver transplants from isolated anti-HBc positive donors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/50\">",
"     50",
"    </a>",
"    ]. Eighteen developed HBV infection compared with only 3 of 651 from anti-HBc negative donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link&amp;anchor=H4#H4\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\", section on 'De novo HBV infection/reactivation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The situation is quite different when kidneys from anti-HBc-positive donors are used. Transmission of HBV is uncommon in this setting and these donor organs are frequently transplanted to expand the pool of available kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/51\">",
"     51",
"    </a>",
"    ]. Recipients should be immunized against HBV prior to their use.",
"   </p>",
"   <p>",
"    Given the availability of vaccination and effective therapies for HBV, transplantation of organs from HBV-infected donors may be considered on an individual basis. These donors are generally not viremic but are anti-HB core antibody positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Hepatitis C virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus is a particular issue in two settings: in the many liver transplant recipients infected with HCV with cirrhosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatocellular carcinoma, and in renal transplant recipients with exposures to HCV from blood products. Unlike HBV, there is no vaccine to prevent acquisition of the disease. There is no consensus on preventive therapy in HCV-infected liver transplant recipients, whereas HCV-infected renal transplant recipients should receive antiviral therapy before transplantation. Therapy is generally based on histopathologic evidence of HCV infection with hepatic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Herpes simplex and varicella-zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of herpes simplex or varicella-zoster infection should receive antiviral prophylaxis during the first three to six months after transplantation and during periods of intensified immunosuppression (treatment of graft rejection) or other \"stresses\" (concomitant infection or surgery).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In programs with a high incidence of infection due to Aspergillus, Histoplasma, or Candida species, both epidemiologic protection (eg, HEPA filtered air supply within the hospital), and fungal prophylaxis (as appropriate to the common isolates) may be utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Choice of regimen'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link\">",
"     \"Infectious complications in liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rates of fungal infections at individual centers and for specific organs vary. A multicenter retrospective study of 1,963 cardiac, heart-lung, and lung transplant recipients in Italy reported fungal infections in 51 (2.6 percent) occurring at a median of 58 days post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/29/10714/abstract/56\">",
"     56",
"    </a>",
"    ]. Aspergillus and Candida spp accounted for 64 and 23 percent of the cases, respectively, with mortality rates of 29 and 33 percent. Rates of fungal infections at individual centers and for specific organs vary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1725996859\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solid organ transplant recipients are considered to be at \"high risk\" for developing infection; individual risk is determined by a relationship between the epidemiologic exposures of the individual and the patient's \"net state of immunosuppression.\" (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of antimicrobial agents for prophylaxis varies by the disease being targeted for prevention and the nature of the recipient's perceived risks. Strategies include universal and targeted prophylaxis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) is given universally to all transplant recipients who do not have sulfa allergies. TMP-SMX is effective for the prevention of Pneumocystis pneumonia (PCP), which occurs in many United States transplantation centers at an overall rate of 10 to 14 percent. It is also effective prophylaxis against Listeria monocytogenes and Toxoplasma gondii. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pneumocystis pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A preemptive approach involves using sensitive assays (eg, antigen detection or molecular assays) to monitor patients at predefined intervals to detect viral replication (eg, viremia) before infection progresses to invasive disease. A positive assay triggers the initiation of antiviral therapy, a reduction in the intensity of immunosuppression,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intensified monitoring. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before transplantation, it is important to establish the patient's immunization history and prior infectious exposures, including travel, to design an appropriate preventative regimen. Laboratory testing for evidence of past infectious exposures is performed to detect asymptomatic infection in the transplant candidate. Some tests are recommended for all patients, while others are useful in selected patients with suggestive epidemiologic risk factors (",
"      <a class=\"graphic graphic_table graphicRef59792 \" href=\"UTD.htm?31/17/32028\">",
"       table 1",
"      </a>",
"      ). Serologic testing is used as an indicator of significant past exposures, and in some cases (eg, cytomegalovirus serostatus) the results are used to guide prophylactic strategies after transplantation. In other cases, the results are used to guide pretransplant immunizations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prophylaxis pretransplant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following transplantation, recipients are vulnerable to nosocomial infections, especially in the early posttransplant period. Patients with prolonged hospitalizations or who require mechanical ventilation are at particularly high risk. The infections commonly encountered in the first month after transplantation are caused by the same nosocomial pathogens that infect other complex postoperative patients. Ninety-five percent of these infections are due to bacterial and fungal agents. However, the difficulty in eradication of such infections is increased in the immunocompromised host. The unique technical features of transplantation (vascular, ureteric, tracheal, biliary anastomoses) predispose to leaks (hematoma, bile, lymphocele). Such fluid collections are a common site of infection. Individuals with chronic infections should have all organisms identified and susceptibility testing performed prior to transplantation. Active infections must be eradicated or controlled prior to transplantation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prophylaxis peritransplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After discharge from the hospital, the recipient is likely to have contacts with a variety of potential pathogens within the community. Most patients receive TMP-SMX (one single strength tablet per day [80 mg",
"      <span class=\"nowrap\">",
"       TMP/160",
"      </span>",
"      mg SMX] or one double strength tablet three to seven times a week) to prevent PCP and certain other infections (eg, Listeria monocytogenes, Toxoplasma gondii). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prophylaxis posttransplant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccination remains the primary method of preventing and controlling influenza and continual changes in viral antigens necessitates annual revision and administration of the influenza vaccine. The intramuscular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      should be given to solid organ transplant recipients. The intranasal live-attenuated influenza vaccine should",
"      <strong>",
"       not",
"      </strong>",
"      be given to solid organ transplant recipients since live viral vaccines are contraindicated in immunocompromised hosts. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Influenza'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytomegalovirus (CMV) is the most common opportunistic pathogen following solid organ transplantation and is an important cause of morbidity and mortality. Patients at highest risk for CMV disease are those who are seronegative for CMV (immunologically naive) and receive an allograft from a seropositive donor",
"      <span class=\"nowrap\">",
"       (D+/R-)",
"      </span>",
"      and those with latent CMV infection who require treatment with antilymphocyte antibodies as a part of induction therapy or for graft rejection. The preferred drugs for CMV prophylaxis are IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Cytomegalovirus'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"       \"Cytomegalovirus infection in renal transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"       \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link&amp;anchor=H15#H15\">",
"       \"Infectious complications in liver transplantation\", section on 'Cytomegalovirus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a history of herpes simplex or varicella-zoster infection should receive antiviral prophylaxis during the first three to six months after transplantation and during periods of intensified immunosuppression (treatment of graft rejection) or other \"stresses\" (concomitant infection or surgery). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Herpes simplex and varicella-zoster'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In programs with a high incidence of infection due to Aspergillus, Histoplasma, or Candida species, both epidemiologic protection (eg, HEPA filtered air supply within the hospital), and fungal prophylaxis (as appropriate to the common isolates) may be utilized. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Fungal infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/1\">",
"      Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/2\">",
"      Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995; 9:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/3\">",
"      Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/4\">",
"      Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/5\">",
"      Manuel O, Kumar D. QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection. Expert Rev Mol Diagn 2008; 8:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/6\">",
"      Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/7\">",
"      Hornum M, Mortensen KL, Kamper AL, Andersen AB. Limitations of the QuantiFERON-TB Gold test in detecting Mycobacterium tuberculosis infection in immunocompromised patients. Eur J Intern Med 2008; 19:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/8\">",
"      Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/9\">",
"      Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/10\">",
"      Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/11\">",
"      Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/12\">",
"      Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/13\">",
"      Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/14\">",
"      Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/15\">",
"      Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990; 11:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/16\">",
"      Kramer MR, Marshall SE, Starnes VA, et al. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993; 153:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/17\">",
"      Maurer JR, Tullis DE, Grossman RF, et al. Infectious complications following isolated lung transplantation. Chest 1992; 101:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/18\">",
"      Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect 1993; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/19\">",
"      Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000; 31:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/20\">",
"      Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004; :CD004291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/21\">",
"      Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/22\">",
"      Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28:250.",
"     </a>",
"    </li>",
"    <li>",
"     VFEND\" Package Insert, May 2002 Pfizer Inc, NY, NY 10017.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/24\">",
"      Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/25\">",
"      Lorf T, Braun F, R&uuml;chel R, et al. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 1999; 42:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/26\">",
"      Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/27\">",
"      Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/28\">",
"      Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72:545.",
"     </a>",
"    </li>",
"    <li>",
"     Package Insert, CANCIDAS\", January 2003, Merck &amp; Co., Inc, Whitehouse Station, NJ 08889.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/30\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/31\">",
"      Kramer MR, Stoehr C, Lewiston NJ, et al. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long? Transplantation 1992; 53:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/32\">",
"      Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/33\">",
"      Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/34\">",
"      Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/35\">",
"      Rodriguez M, Sifri CD, Fishman JA. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004; 38:e76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/36\">",
"      Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/37\">",
"      Derouin F, Pelloux H, ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 2008; 14:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/38\">",
"      Gallino A, Maggiorini M, Kiowski W, et al. Toxoplasmosis in heart transplant recipients. Eur J Clin Microbiol Infect Dis 1996; 15:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/39\">",
"      Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/40\">",
"      Baden LR, Katz JT, Franck L, et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation 2003; 75:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/41\">",
"      Wreghitt TG, Gray JJ, Pavel P, et al. Efficacy of pyrimethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patients. Transpl Int 1992; 5:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/42\">",
"      Mu&ntilde;oz P, Arencibia J, Rodr&iacute;guez C, et al. Trimethoprim-sulfamethoxazole as toxoplasmosis prophylaxis for heart transplant recipients. Clin Infect Dis 2003; 36:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/43\">",
"      Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/44\">",
"      Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/45\">",
"      Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/46\">",
"      Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc 1998; 30:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/47\">",
"      Engler SH, Sauer PW, Golling M, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 2001; 13:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/48\">",
"      McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/49\">",
"      Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167:630.",
"     </a>",
"    </li>",
"    <li>",
"     Dickson, RC, Everhart, JE, Lake, JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/51\">",
"      Madayag RM, Johnson LB, Bartlett ST, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/52\">",
"      Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/53\">",
"      Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/54\">",
"      Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/55\">",
"      Hadley S, Samore MH, Lewis WD, et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/29/10714/abstract/56\">",
"      Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1408 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-110.137.129.113-D39946C7A2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10714=[""].join("\n");
var outline_f10_29_10714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1725996859\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROPHYLAXIS PRETRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Screening for latent TB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROPHYLAXIS PERITRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibacterial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antifungal prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROPHYLAXIS POSTTRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pneumocystis pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Influenza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Hepatitis B virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Herpes simplex and varicella-zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1725996859\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1408\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1408|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/17/32028\" title=\"table 1\">",
"      Pretransplant lab evaluation SOT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/1/42012\" title=\"table 2\">",
"      Transplant fungal prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_29_10715="Contraindications elective surgery in patients with liver disease";
var content_f10_29_10715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to elective surgery in patients with liver disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acute alcoholic hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute viral hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child's class C cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fulminant hepatic failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe chronic hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe coagulopathy (prolongation of the prothrombin time",
"&gt;3 seconds despite vitamin K administration; platelet count &lt;",
"50,000/mm3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Severe extrahepatic complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiomyopathy, heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoxemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Friedman LS. The risk of surgery in patients with liver disease. Hepatology 1999; 29:1617. Copyright &copy; 1999 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10715=[""].join("\n");
var outline_f10_29_10715=null;
var title_f10_29_10716="Cell types involved in ACD";
var content_f10_29_10716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cell types involved in ACD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cell type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function in ACD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Langerhans cells",
"       </td>",
"       <td>",
"        Originally thought to be the primary APC, they may also have a regulatory function. Other APCs such as dermal dendritic cells may be involved in all phases of ACD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratinocytes",
"       </td>",
"       <td>",
"        Facilitate T cell infiltration into the epidermis by expressing specific receptors that bind to molecules located on T cell surface. They are involved in the initiation phase of ACD by producing cytokines that mobilize LCs to migrate and in the termination of ACD through tolerogenic antigen presentation and production of IL-10 and IL-16, which recruit T regulatory cells.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD8+ T cells",
"       </td>",
"       <td>",
"        Major effector cell in ACD and source of IFN-gamma production.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4+ T cells",
"       </td>",
"       <td>",
"        Some experimental data support a role for Th1 memory/effector cells in ACD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-1 cells (a type of B-cells)",
"       </td>",
"       <td>",
"        Produce IgM antibodies in response to IL-4, leading to complement activation and leukocyte chemotaxis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invariant natural killer T cells",
"       </td>",
"       <td>",
"        Respond to unidentified endogenous glycolipids after hapten exposure which leads to IL-4 production to activate B-1 cells.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T-regulatory cells",
"       </td>",
"       <td>",
"        T cell subsets (CD4+, CD25high, Foxp3 transcription factor, CTLA-4+) that function to suppress the T cell-dependent inflammatory response seen in ACD and are critical to hapten tolerance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural killer cells",
"       </td>",
"       <td>",
"        Member of the innate immune system recently shown to exhibit memory and antigen specificity in a model of murine ACD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mast cells",
"       </td>",
"       <td>",
"        Produce TNF-alpha, which induces DC migration; promote T cell infiltration through release of IL-3, induce T cell proliferation and activation; release mediators that promote inflammation; and may function in antigen presentation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gober MD, Gaspari AA. Allergic contact dermatitis. Curr Dir Autoimmun 2008; 10:1. Copyright &copy; 2008 S. Karger AG, Basel. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10716=[""].join("\n");
var outline_f10_29_10716=null;
var title_f10_29_10717="Rapid diuretic therapy in cirrhosis";
var content_f10_29_10717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing the effect of rapid diuretic therapy on plasma volume in cirrhotic patients with ascites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 230px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of rapid diuretic therapy on the plasma volume in patients with cirrhosis and ascites with or without peripheral edema. Compared to those with edema (column one) or untreated patients (column two), the patients without peripheral edema (including edematous patients in column one studied after peripheral edema but not ascites had resolved) developed significant plasma volume depletion due to an inability to adequately mobilize the ascitic fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Pockros PJ, Reynolds TB. Gastroenterology 1986; 90:1827.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10717=[""].join("\n");
var outline_f10_29_10717=null;
var title_f10_29_10718="Prevalence of comorbid depression in anxiety disorders";
var content_f10_29_10718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F86955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F86955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of comorbid depression in anxiety disorders (data from large epidemiological surveys)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author/year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Population/study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anxiety disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence of comorbid MDD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schneier et al.",
"        <br/>",
"        1992",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        ECA",
"       </td>",
"       <td>",
"        SAD",
"       </td>",
"       <td>",
"        16.6% (lifetime)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Flint",
"        <br/>",
"        1994",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        ECA",
"       </td>",
"       <td>",
"        All anxiety disorders",
"       </td>",
"       <td>",
"        21% (12-month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GAD",
"       </td>",
"       <td>",
"        60% (12-month)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Wittchen et al.",
"        <br/>",
"        1994",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        NCS",
"       </td>",
"       <td>",
"        GAD",
"       </td>",
"       <td>",
"        38.6% (30 day GAD); 62.4% (lifetime)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Kessler et al.",
"        <br/>",
"        1995",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        NCS",
"       </td>",
"       <td>",
"        PTSD",
"       </td>",
"       <td>",
"        47.9% (males, lifetime); 48.5% (females, lifetime)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Magee et al.",
"        <br/>",
"        1996",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        NCS",
"       </td>",
"       <td>",
"        SAD",
"       </td>",
"       <td>",
"        37.2% (lifetime)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AGOR",
"       </td>",
"       <td>",
"        45.9% (lifetime)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SP",
"       </td>",
"       <td>",
"        42.3% (lifetime)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lieb et al.",
"        <br/>",
"        2005",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        ESEMeD",
"       </td>",
"       <td>",
"        GAD",
"       </td>",
"       <td>",
"        59% (12-month)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Alonso et al.",
"        <br/>",
"        2007",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td rowspan=\"6\">",
"        ESEMeD",
"       </td>",
"       <td>",
"        SAD",
"       </td>",
"       <td>",
"        14.5% (all 12-month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GAD",
"       </td>",
"       <td>",
"        37.1%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PTSD",
"       </td>",
"       <td>",
"        7.8%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PD",
"       </td>",
"       <td>",
"        29.8%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AGOR",
"       </td>",
"       <td>",
"        15.5%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SP",
"       </td>",
"       <td>",
"        15.5%",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Eisenberg et al.",
"        <br/>",
"        2007",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        WHO",
"       </td>",
"       <td>",
"        GAD",
"       </td>",
"       <td>",
"        30.4% (2 weeks)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PD",
"       </td>",
"       <td>",
"        9.4% (2 weeks)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Gabilondo et al.",
"        <br/>",
"        2010",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td rowspan=\"6\">",
"        ESEMeD",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        7.7% (all 12-month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GAD",
"       </td>",
"       <td>",
"        15%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PTSD",
"       </td>",
"       <td>",
"        7.3%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PD",
"       </td>",
"       <td>",
"        9%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AGOR",
"       </td>",
"       <td>",
"        3%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SP",
"       </td>",
"       <td>",
"        14.4%",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Kessler et al.",
"        <br/>",
"        2010",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        WHO",
"       </td>",
"       <td>",
"        Any anxiety disorder",
"       </td>",
"       <td>",
"        49.7% (12-month)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top \">",
"       <td>",
"        Ruscio et al.",
"        <br/>",
"        2010",
"        <sup>",
"         [11]",
"        </sup>",
"       </td>",
"       <td>",
"        NCS-R",
"       </td>",
"       <td>",
"        OCD",
"       </td>",
"       <td>",
"        40.7% (lifetime)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Kessler et al.",
"        <br/>",
"        1999",
"        <sup>",
"         [12]",
"        </sup>",
"       </td>",
"       <td>",
"        NCS",
"       </td>",
"       <td rowspan=\"2\">",
"        GAD",
"       </td>",
"       <td>",
"        58.1% (12-month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MDUSS",
"       </td>",
"       <td>",
"        69.7% (12-month)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECA: Epidemiologic Catchment Area Study; NCS: National Comorbidity Survey; ESEMeD: European Study of the Epidemiology of Mental Disorders; WHO: World Health Organization Mental Health Survey Initiative; NCS-R: National Comorbidity Survey-Replication; MDUSS: Midlife Development in the United States Survey; AGOR: agoraphobia; GAD: generalized anxiety disorder; PD: panic disorder; PTSD: posttraumatic stress disorder; OCD: obsessive-compulsive disorder; SP: specific/simple phobia; SAD: social anxiety disorder; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen 49:282, 1992.",
"      </li>",
"      <li>",
"       Flint AJ. Epidemiology and Comorbidity of Anxiety Disorders in the Elderly. Am J Psychiatry 151:640, 1994.",
"      </li>",
"      <li>",
"       Wittchen HU, Zhao SY, Kessler RC, Eaton WW. Dsm-Iii-R Generalized Anxiety Disorder in the National-Comorbidity-Survey. Arch Gen Psychiatry 51:355, 1994.",
"      </li>",
"      <li>",
"       Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic-Stress-Disorder in the National Comorbidity Survey. Arch Gen Psychiatry 52:1048, 1995.",
"      </li>",
"      <li>",
"       Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the national comorbidity survey. Arch Gen Psychiatry 53:159, 1996.",
"      </li>",
"      <li>",
"       Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. European Neuropsychopharmacology 15:445, 2005.",
"      </li>",
"      <li>",
"       Alonso J, L&eacute;pine JP, ESEMeD/MHEDEA 2000 Scientific Committee. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry 68 Suppl 2:3, 2007.",
"      </li>",
"      <li>",
"       Eisenberg D, Gollust SE, Golberstein E, Hefner JL. Prevalence and correlates of depression, anxiety, and suicidality among university students. Am J Orthopsychiatry 77:534, 2007.",
"      </li>",
"      <li>",
"       Gabilondo A, Rojas-Farreras S, Vilagut G, Haro JM, Fernandez A, Pinto-Meza A, et al. Epidemiology of major depressive episode in a southern European country: Results from the ESEMeD-Spain project. J Affect Disord 120:76, 2010.",
"      </li>",
"      <li>",
"       Kessler RC, Birnbaum HG, Shahly V, et al. Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative. Depress Anxiety 27:351, 2010.",
"      </li>",
"      <li>",
"       Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15:53, 2010.",
"      </li>",
"      <li>",
"       Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915, 1999.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10718=[""].join("\n");
var outline_f10_29_10718=null;
var title_f10_29_10719="EB extracutaneous complications";
var content_f10_29_10719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Extracutaneous manifestations and complications of inherited epidermolysis bullosa (EB)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Predominant EB subtypes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Nail apparatus",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        Peri- or subungual blistering, hemorrhages and nail bed hyperkeratosis with onycholysis, onychomadesis; periodic nail shedding and regrowth with progressive onychodystrophy (EBS, JEB, DEB) +/- onychogryphosis (EBS, JEB)",
"       </td>",
"       <td rowspan=\"7\">",
"        Severe EBS subtypes (excluding localized EBS, EBS migratory circinate, EBS with pyloric atresia); most JEB patients; DEB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paronychia-like lesions and nail loss with nail bed erosions and development of sub- and periungual granulation tissue soon after birth (JEB-H and LOC-syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete nail loss, nail bed and matrix scarring, mitten deformity (DEB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thin, brittle, short atrophic nails due to nail matrix damage by repetitive blistering (JEB, DEB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Few nails affected in localized DEB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autosomal dominant trait of toenail onychodystrophy in a child may be sign of DEB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parrot beak nail deformity from recurrent blistering in distal fingers resulting in soft tissue and bone reabsorption with nail bending around shortened fingertip (KS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Hair",
"       </td>",
"       <td>",
"        Increased hair and skin fragility due to deficient stabilization of the upper permanent portion of the follicle (infundibulum, isthmus, bulge region) to the surrounding connective tissues (DEB)",
"       </td>",
"       <td rowspan=\"7\">",
"        EBS, JEB, DEB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cicatricial alopecia secondary to blistering (JEB, DEB) or infection involving interfollicular epidermis and upper portion of hair follicle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient, reversible telogen effluvium due to anemia or sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sparse, short, dry, curly, woolly hair; hypotrichosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent eyebrows and eyelashes (ectodermal dysplasia-skin fragility syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete absence of hair, eyebrows, eyelashes, vellus hairs (lethal acantholytic EBS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary scarring alopecia (JEB with pyloric atresia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Eye",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        Red watery eyes, photophobia, ocular pain; conjunctival injection, edema, blisters; subconjunctival hemorrhage, blepharoconjunctivitis (sgRDEB, RDEB-I), exposure keratopathy",
"       </td>",
"       <td rowspan=\"5\">",
"        sgRDEB, RDEB-O, JEB-H, JEB-nH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corneal bullae, erosion, ulceration, abrasions, pitting, opacities, scars; peripheral corneal vascularization, corneal pannus formation, limbal broadening, cornea plana, sclerocornea, cataracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyelid blisters or ectropion with exuberant granulation tissue (JEB-H), eyelid scarring, pseudopterygium, symblepharon (JEB, RDEB), ankyloblepharon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lacrimal duct obstruction (RDEB-I, JEB-H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refractive errors, amblyopia, strabismus, lens subluxation, posterior vitreous detachment, impaired vision (sgRDEB, RDEB-I), blindness (sgRDEB)",
"        <sup>",
"         [2,3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        Oral cavity",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        <strong>",
"         Soft tissues",
"        </strong>",
"       </td>",
"       <td rowspan=\"12\">",
"        sgRDEB, JEB, severe subtypes of EBS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucosal fragility, blistering, ulceration, mostly localized (EBS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Significant involvement and oral scarring (EBS-DM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Variable blistering and ulceration; exuberant perioral granulation tissue resulting in a reduction of the oral opening (microstomia) and loss of tissue mobility in lips and perioral tissues (JEB-H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Involvement from mild to severe; extreme fragility evident shortly after birth with inability to suckle (sgRDEB, RDEB-O)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Restricted oral aperture, ankyloglossia, obliteration of vestibules, loss of lingual papillae, ablated palatal rugae; intraoral keratocysts (milia), elevated risk for intraoral squamous cell carcinoma (sgRDEB)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Early onset periodontal disease, gingival inflammation and hyperplasia; sometimes severe oral blistering in neonates and infants, decreasing with age (KS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hard tissues",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal dentition, caries risk not increased (EBS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enamel lesions including pitting, horizontal hypoplastic bands, white mottled enamel, generalized hypoplasia, abnormal tooth eruption; increased risk of dental caries (JEB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal enamel (type VII collagen not expressed by ameloblasts); excessive dental caries, extensive tooth plaque formation and bacterial inoculation (DEB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal dentition; risk of dental caries unknown (KS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Gastrointestinal tract",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        Painful esophageal blistering, erosions, scarring, web formation, stenosis, strictures; hiatus hernia, abnormal esophageal peristalsis, atony, spontaneous perforation (sgRDEB)",
"       </td>",
"       <td rowspan=\"7\">",
"        sgRDEB, RDEB-I, JEB-H",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastroesophageal reflux disease common in more severe forms (RDEB, JEB-H, EBS-DM, JEB-nH) and prominent in pediatric populations; peptic ulcer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malabsorption, diarrhea; protein losing enteropathy; irritable bowel disease; inflammatory bowel disease (EBS, DEB",
"        <sup>",
"         [6]",
"        </sup>",
"        ); diverticular disease; megacolon; colon perforation and peritonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectal tears, prolapse, strictures; perianal fistulae; hemorrhoids, intussusception; megarectum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia, deficiencies of specific nutrients and vitamins (iron, selenium, zinc, vitamins A, B6, B12, C, D), hypoalbuminemia, osteoporosis/osteopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercatabolic state with failure to thrive (sgRDEB, JEB-H, EBS-DM, JEB-nH, RDEB-I; RDEB-O)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        Genitourinary tract",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        Dysuria",
"       </td>",
"       <td rowspan=\"9\">",
"        JEB-H, RDEB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blistering, fibrosis and scarring of glans penis; urethral meatal stenosis (RDEB); chronic inflammation of detrusor muscles secondary to exposure of denuded tissues to urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral diverticula, penile and bulbar urethral strictures, hypospadias, epispadias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erosion or ulcerations on labia (RDEB-I), partial fusion of labia, narrowing of vaginal vestibule; urinary reflux into vagina and filling of uterine cavity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macroscopic blisters within the bladder, bladder edema, bladder cystitis, reduced bladder capacity, thickened bladder wall, bladder exstrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microscopic cleft formation within bladder, renal pelvis, ureter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary retention, stenosis or obstruction of the ureterovesical junction, ureteral fibrosis and stenosis, ureteral reflux with posterior urethral valves, hydroureter, hydronephrosis, renal pelvis stenosis, pyelocaliectasis, ureterectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyelonephritis, poststreptococcal, IgA, mesangial glomerulonephritis (RDEB); renal amyloidosis (RDEB), recurrent urinary tract infections, recurrent urosepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal insufficiency and failure (sgRDEB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        Ear, nose, throat and upper airway",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        <strong>",
"         Ear",
"        </strong>",
"       </td>",
"       <td rowspan=\"12\">",
"        JEB (including LOC syndrome), RDEB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trauma induced blistering, erosions, crusting on auricle and external auditory canal; secondary microbial colonization and infections (JEB), scarring/stenosis (DEB); auricular milia formation (DEB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Otitis media and externa (JEB-H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bilateral sensorineural deafness (RDEB, RDEB-I)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Nose",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erosions, crusting, around nares and within nostrils; rhinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granulation tissue (JEB-H) resulting in airway narrowing and repeated bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No increased frequency of atopy among any EB subtype",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oropharynx",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blisters, erosions, scarring, stenosis (JEB; DEB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Larynx, trachea",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blisters, erosions, inflammation and soft tissue edema, scar formation along luminal surfaces including vocal cords (hoarse cry or voice; stridor); cysts; webbing, stenosis, strictures; complete or partial luminal occlusion secondary to exuberant granulation tissue with secondary aspiration pneumonitis or acute airway occlusion (JEB-H, LOC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Musculoskeletal system and heart",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        Pseudosyndactyly and total encasement of digits (sgRDEB; RDEB-I; infrequently in DDEB, cicatricial JEB, EBS-DM); contractures of hands (adduction contractures of thumb), feet, popliteal and antecubital fossae, and axillary vaults; progressive functional disability (difficulties in weight bearing, standing, walking; reduced fine manipulative skill; loss of digital prehension); muscle atrophy; bone absorption",
"       </td>",
"       <td rowspan=\"3\">",
"        sgRDEB, RDEB-I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteopenia, osteoporosis (RDEB) consequent to restricted mobility and weight-bearing activity (painful skin wounds, contractures); impaired nutritional intake despite greater requirements (calcium, vitamin D, anemia); reduced sunlight exposure (restricted outdoor activities, extensive bandaging); induction of catabolic osteoclastic activity by proinflammatory cytokines in the course of chronic inflammation and chronic skin infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathy (sgRDEB; rarely RDEB-O; JEB) due to malnutrition and micronutrient (selenium and carnitine) deficiency",
"        <sup>",
"         [9]",
"        </sup>",
"        , chronic anemia, transfusion-associated iron overload, viral myocarditis; precipitating or exacerbating cardiotoxic medications (amitriptyline, cisapride); may present in early childhood",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EBS: epidermolysis bullosa simplex; EBS-DM: epidermolysis bullosa simplex Dowling-Meara; EBS-MD: epidermolysis bullosa simplex with muscular dystrophy; JEB: junctional epidermolysis bullosa; JEB-H: junctional epidermolysis bullosa Herlitz; JEB-nH: junctional epidermolysis bullosa non-Herlitz; LOC syndrome: laryngo-oculo-cutaneous syndrome; DEB: dystrophic epidermolysis bullosa; RDEB: recessive dystrophic epidermolysis bullosa; DDEB: dominant dystrophic epidermolysis bullosa; sgRDEB: severe generalized dystrophic epidermolysis bullosa; RDEB-O: other severe generalized epidermolysis bullosa; RDEB-I: inverse recessive dystrophic epidermolysis bullosa; KS: Kindler syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Tosti A, de Farias DC, Murrell DF. Nail involvement in epidermolysis bullosa. Dermatol Clin 2010; 28:153.",
"      </li>",
"      <li>",
"       Figueira EC, Murrell DF, Coroneo MT. Ophthalmic involvement in inherited epidermolysis bullosa. Dermatol Clin 2010; 28:143.",
"      </li>",
"      <li>",
"       Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol 2009; 61:367.",
"      </li>",
"      <li>",
"       Wright JT. Oral manifestations in the epidermolysis bullosa spectrum. Dermatol Clin 2010; 28:159.",
"      </li>",
"      <li>",
"       Fine JD, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience,1986-2006. J Am Acad Dermatol 2009; 60:203.",
"      </li>",
"      <li>",
"       Shah N, Freeman E, Martinez A, et al. Histopathological features of gastrointestinal mucosal biopsy specimens in children with epidermolysis bullosa. J Clin Pathol 2007; 60:843.",
"      </li>",
"      <li>",
"       Fine JD, Johnson LB, Weiner M, Suchindran C. Tracheolaryngeal complications of inherited epidermolysis bullosa: cumulative experience of the national epidermolysis bullosa registry. Laryngoscope 2007; 117:1652.",
"      </li>",
"      <li>",
"       Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol 2009; 61:387.",
"      </li>",
"      <li>",
"       Lara-Corrales I, Mellerio JE, Martinez AE, et al. Dilated cardiomyopathy in epidermolysis bullosa: a retrospective, multicenter study. Pediatr Dermatol 2010; 27:238.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_29_10719=[""].join("\n");
var outline_f10_29_10719=null;
